,Sample ID,EXTERNAL Sample ID ,Tissue/Cell line,Extra,Note,Project name
0,DAH46,VOA800,Clear cell ovarian cancer--FFPE,"[{'Note': '', 'Tissue/Cell line': 'Clear cell ovarian cancer--FFPE', 'EXTERNAL Sample ID ': 'VOA800'}, {'Note': '', 'Tissue/Cell line': 'Clear cell ovarian cancer--Frozen', 'EXTERNAL Sample ID ': 'VOA800'}, {'Note': '', 'Tissue/Cell line': 'Clear cell ovarian cancer--FFPE WGA', 'EXTERNAL Sample ID ': 'VOA800'}, {'Note': '', 'Tissue/Cell line': 'Clear cell ovarian cancer--Frozen WGA', 'EXTERNAL Sample ID ': 'VOA800'}]",,['exon capture test']
1,DAH46N,VOA800,Matched normal--FFPE,"[{'Note': '', 'Tissue/Cell line': 'Matched normal--FFPE', 'EXTERNAL Sample ID ': 'VOA800'}, {'Note': '', 'Tissue/Cell line': 'Matched normal--Buffy coat', 'EXTERNAL Sample ID ': 'VOA800'}, {'Note': '', 'Tissue/Cell line': 'Matched normal--FFPE WGA', 'EXTERNAL Sample ID ': 'VOA800'}, {'Note': '', 'Tissue/Cell line': 'Matched normal--Buffy coat WGA', 'EXTERNAL Sample ID ': 'VOA800'}]",,['exon capture test']
2,SA002,VBA0038,DNA fr.pleural effusion cells  from Breast Ca. patient,"[{'Note': '', 'Tissue/Cell line': 'DNA fr.pleural effusion cells  from Breast Ca. patient', 'EXTERNAL Sample ID ': 'VBA0038'}, {'Note': '', 'Tissue/Cell line': 'RNA fr. Human pleural effusion cells', 'EXTERNAL Sample ID ': 'VBA0038'}, {'Note': '', 'Tissue/Cell line': 'RNA fr. Human pleural effusion cells', 'EXTERNAL Sample ID ': 'VBA0038'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0038'}, {'Note': 'HS0296 library number without exon capture', 'Tissue/Cell line': 'Lobular Breast tumour--pleural effusion gDNA', 'EXTERNAL Sample ID ': 'VBA0038'}, {'Note': 'HS0296 library number without exon capture', 'Tissue/Cell line': 'Lobular Breast tumour--pleural effusion gDNA', 'EXTERNAL Sample ID ': 'VBA0038'}, {'Note': 'HS0511 library number without exon capture', 'Tissue/Cell line': 'Lobular Breast tumour--pleural effusion cDNA', 'EXTERNAL Sample ID ': 'VBA0038'}, {'Note': 'HS0511 library number without exon capture', 'Tissue/Cell line': 'Lobular Breast tumour--pleural effusion cDNA WGA', 'EXTERNAL Sample ID ': 'VBA0038'}, {'Note': 'HS0296 library number without exon capture', 'Tissue/Cell line': 'Lobular Breast tumour--pleural effusion gDNA WGA', 'EXTERNAL Sample ID ': 'VBA0038'}, {'Note': 'at GSC from previous submissions', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'VBA0038'}]",,"['', 'exon capture test', 'triple negatives', 'lobular breast']"
3,SA002N,VBA0038,Lob Breast pleural effusion-buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Lob Breast pleural effusion-buffy coat', 'EXTERNAL Sample ID ': 'VBA0038'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'VBA0038'}]",,"['exon capture test', 'triple negatives']"
4,SA011,200+bp gel fraction ,"HS0583 is primary tumour for VBA0038, HS0580 is germline DNA for VBA0038","[{'Note': 'also HS0583', 'Tissue/Cell line': 'HS0583 is primary tumour for VBA0038, HS0580 is germline DNA for VBA0038', 'EXTERNAL Sample ID ': '200+bp gel fraction '}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '200+bp gel fraction '}]",also HS0583,['lobular breast']
5,SA012 (WT Testes),H3K4me3 ChIP,Mouse testes,"[{'Note': 'ID: 308H2AAXX_4', 'Tissue/Cell line': 'Mouse testes', 'EXTERNAL Sample ID ': 'H3K4me3 ChIP'}, {'Note': 'ID: 308H2AAXX_5', 'Tissue/Cell line': 'Mouse testes', 'EXTERNAL Sample ID ': 'H3K27me3 ChIP'}, {'Note': 'ID: 30WLJAAXX_7', 'Tissue/Cell line': 'Mouse testes', 'EXTERNAL Sample ID ': 'H3K9me3 ChIP'}]",ID: 308H2AAXX_4,['mll5']
6,SA013 (KO Testes),H3K4me3 ChIP,Mouse testes,"[{'Note': 'ID: 308H2AAXX_6', 'Tissue/Cell line': 'Mouse testes', 'EXTERNAL Sample ID ': 'H3K4me3 ChIP'}, {'Note': 'ID: 308H2AAXX_7', 'Tissue/Cell line': 'Mouse testes', 'EXTERNAL Sample ID ': 'H3K27me3 ChIP'}, {'Note': 'ID: 30WMAAAXX_7', 'Tissue/Cell line': 'Mouse testes', 'EXTERNAL Sample ID ': 'H3K9me3 ChIP'}]",ID: 308H2AAXX_6,['mll5']
7,SA014,184-hTERT L2 passage 9,RNA fr. 184-hTERT clonal line L2,"[{'Note': '', 'Tissue/Cell line': 'RNA fr. 184-hTERT clonal line L2', 'EXTERNAL Sample ID ': '184-hTERT L2 passage 9'}, {'Note': 'with post pcr purification', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': ''}]",,['h-tert']
8,SA015,184-hTERT L9 passage 11,RNA fr. 184-hTERT clonal line L9,"[{'Note': '', 'Tissue/Cell line': 'RNA fr. 184-hTERT clonal line L9', 'EXTERNAL Sample ID ': '184-hTERT L9 passage 11'}, {'Note': 'with post pcr purification', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': ''}]",,['h-tert']
9,SA017,IDC - TTR 0001003,RNA fr.hu breast tumour tissue ,"[{'Note': '', 'Tissue/Cell line': 'RNA fr.hu breast tumour tissue ', 'EXTERNAL Sample ID ': 'IDC - TTR 0001003'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'IDC - TTR 0001003'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001003'}]",,['triple negatives']
10,SA018,IDC - TTR 0001005,RNA fr.hu breast tumour tissue ,"[{'Note': '', 'Tissue/Cell line': 'RNA fr.hu breast tumour tissue ', 'EXTERNAL Sample ID ': 'IDC - TTR 0001005'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001005'}]",,['triple negatives']
11,SA028,IDC - TTR0001001,RNA fr.hu breast tumour tissue ,"[{'Note': 'New RNA submitted due to first batch having low RIN', 'Tissue/Cell line': 'RNA fr.hu breast tumour tissue ', 'EXTERNAL Sample ID ': 'IDC - TTR0001001'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'TTR0001001'}]",New RNA submitted due to first batch having low RIN,['triple negatives']
12,SA029,IDC- TTR0001002,RNA fr.hu breast tumour tissue ,"[{'Note': '', 'Tissue/Cell line': 'RNA fr.hu breast tumour tissue ', 'EXTERNAL Sample ID ': 'IDC- TTR0001002'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001002'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'TTR0001002'}]",,['triple negatives']
13,SA030,IDC - TTR0001004,RNA fr.hu breast tumour tissue ,"[{'Note': '', 'Tissue/Cell line': 'RNA fr.hu breast tumour tissue ', 'EXTERNAL Sample ID ': 'IDC - TTR0001004'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001004'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'TTR0001004'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'TTR0001004'}]",,['triple negatives']
14,SA031,IDC - VBA0132,DNA fr.hu breast tumour tissue ,"[{'Note': '', 'Tissue/Cell line': 'DNA fr.hu breast tumour tissue ', 'EXTERNAL Sample ID ': 'IDC - VBA0132'}, {'Note': '', 'Tissue/Cell line': 'RNA fr.hu breast tumour tissue ', 'EXTERNAL Sample ID ': 'IDC - VBA0132'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'VBA0132'}]",,['triple negatives']
15,SA036,,HCT116,"[{'Note': '', 'Tissue/Cell line': 'HCT116', 'EXTERNAL Sample ID ': ''}, {'Note': '', 'Tissue/Cell line': 'HCT116', 'EXTERNAL Sample ID ': ''}, {'Note': 'second extraction had to be done because of the poor quality - library construction failes again and more DNA was submitted on July 25, 2014', 'Tissue/Cell line': 'HCT116 ', 'EXTERNAL Sample ID ': 'HCT116_WT'}]",,"['sirna screen', 'cell line']"
16,SA037,,HCT116,"[{'Note': '', 'Tissue/Cell line': 'HCT116', 'EXTERNAL Sample ID ': ''}, {'Note': '', 'Tissue/Cell line': 'HCT116', 'EXTERNAL Sample ID ': ''}, {'Note': '', 'Tissue/Cell line': 'HCT116', 'EXTERNAL Sample ID ': 'HCT116-BRCA2-/- clone 18'}]",,"['sirna screen', 'cell line']"
17,SA038,,HCT116,"[{'Note': '', 'Tissue/Cell line': 'HCT116', 'EXTERNAL Sample ID ': ''}, {'Note': '', 'Tissue/Cell line': 'HCT116', 'EXTERNAL Sample ID ': ''}, {'Note': '', 'Tissue/Cell line': 'HCT116', 'EXTERNAL Sample ID ': 'HCT116-BRCA2-/- clone 46'}]",,"['sirna screen', 'cell line']"
18,SA041,H3K4me3,,"[{'Note': 'ID: 313HYAAXX_7', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'H3K4me3'}, {'Note': 'ID: 30WJVAAXX_1', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'H3K9me3'}, {'Note': 'ID: 30WJVAAXX_2', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'H3K27me3'}, {'Note': 'ID: 30WJVAAZZ_3', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'H3K4me1'}, {'Note': 'ID: 313RRAAXX_7', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'H4Ac'}]",ID: 313HYAAXX_7,['mll5']
19,SA042,H3K4me3,,"[{'Note': 'ID: 30WJVAAXX_4', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'H3K4me3'}, {'Note': 'ID: 30WJVAAXX_5', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'H3K9me3'}, {'Note': 'ID: 30WJVAAXX_6', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'H3K27me3'}, {'Note': 'ID: 313KTAAXX_6', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'H3K4me1'}, {'Note': 'ID: 313KTAAXX_7', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'H4Ac'}]",ID: 30WJVAAXX_4,['mll5']
20,SA051,IDC - TTR0001012,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001012'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001012'}]",,['triple negatives']
21,SA052,IDC - TTR0001013,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001013'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001013'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'TTR0001013'}]",,['triple negatives']
22,SA053,IDC - TTR0001015,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001015'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001015'}]",,['triple negatives']
23,SA054,IDC - TTR0001023,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001023'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': ''}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001023'}]",,"['', 'triple negatives']"
24,SA056,IDC - TTR0001025,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001025'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001025'}]",,['triple negatives']
25,SA063,IDC - TTR0001042,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001042'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001042'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001042'}]",,['triple negatives']
26,SA065,IDC - TTR0001050,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001050'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001050'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001050'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'TTR0001050'}]",,['triple negatives']
27,SA067,IDC - TTR0001055,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001055'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001055'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'TTR0001055'}]",,['triple negatives']
28,SA068,IDC - TTR0001044,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001044'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001044'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001044'}]",,['triple negatives']
29,SA069,IDC - TTR0001051,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001051'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001051'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001051'}]",,['triple negatives']
30,SA070,IDC - TTR0001053,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001053'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001053'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001053'}]",,['triple negatives']
31,SA071,IDC - TTR0001007,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001007'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001007'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001007'}]",,['triple negatives']
32,SA072,IDC - TTR0001008,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001008'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001008'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001008'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'TTR0001008 '}]",,['triple negatives']
33,SA073,IDC - TTR0001011,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001011'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001011'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001011'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': ' TTR0001011'}]",,['triple negatives']
34,SA074,IDC - TTR0001026,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001026'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001026'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001026'}]",,['triple negatives']
35,SA075,IDC - TTR0001027,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001027'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001027'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001027'}]",,['triple negatives']
36,SA076,IDC - TTR0001047,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001047'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001047'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001047'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'TTR0001047'}]",,['triple negatives']
37,SA077,IDC - TTR0001070,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001070'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001070'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001070'}]",,['triple negatives']
38,SA080,IDC - TTR0001006,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001006'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001006'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001006'}]",,['triple negatives']
39,SA083,IDC - TTR0001073,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001073'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'IDC - TTR0001073'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001073'}]",,['triple negatives']
40,SA084,Camb 82658,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 82658'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 82658'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 82658'}]",,['triple negatives']
41,SA085,Camb 83133,Breast Tumour,"[{'Note': 'library constructed in 2009 and sequenced on HiSeq in 2011', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 83133'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 83133'}, {'Note': 'on HOLD-inadequate amoutn of T DNA', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 83133'}, {'Note': 'previous genome libraries gave low coverage in sequencing; therefore, new ones are made to get to 30x coverage - library construction using SPRI-TE platform', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'BB98.0032'}]",library constructed in 2009 and sequenced on HiSeq in 2011,['triple negatives']
42,SA089,TTR0001009,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001009'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001009'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001009'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'TTR0001009'}]",,['triple negatives']
43,SA090,TTR0001010,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001010'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001010'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'TTR0001010'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'TTR0001010'}]",,['triple negatives']
44,SA092,Camb 83004,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 83004'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 83004'}, {'Note': 'previously on HOLD-released for EXCAP (50 Mb) on Dec 18th', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 83004'}]",,['triple negatives']
45,SA093,Camb 83021,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 83021'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 83021'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 83021'}]",,['triple negatives']
46,SA094,Camb 83233,Breast Tumour,"[{'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 83233'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 83233'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'Camb 83233'}]",,['triple negatives']
47,SA095,VBA0082,Breast Tumour,"[{'Note': 'library constructed in 2009 and sequenced on HiSeq in 2011', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'VBA0082'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour', 'EXTERNAL Sample ID ': 'VBA0082'}]",library constructed in 2009 and sequenced on HiSeq in 2011,['triple negatives']
48,SA208,CT110,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT110'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour--From Alberta', 'EXTERNAL Sample ID ': 'CT110'}]",,['triple negatives']
49,SA209,MT1177,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1177'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour--From Alberta', 'EXTERNAL Sample ID ': 'MT1177'}]",,['triple negatives']
50,SA210,MT0882,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0882'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour--From Alberta', 'EXTERNAL Sample ID ': 'MT0882'}]",,['triple negatives']
51,SA211,RT352,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'RT352'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour--From Alberta', 'EXTERNAL Sample ID ': 'RT352'}]",,['triple negatives']
52,SA212,MT0578,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0578'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour--From Alberta', 'EXTERNAL Sample ID ': 'MT0578'}]",,['triple negatives']
53,SA213,MT0620,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0620'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour--From Alberta', 'EXTERNAL Sample ID ': 'MT0620'}]",,['triple negatives']
54,SA214,MT1077,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1077'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour--From Alberta', 'EXTERNAL Sample ID ': 'MT1077'}]",,['triple negatives']
55,SA215,CT34,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT34'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour--From Alberta', 'EXTERNAL Sample ID ': 'CT34'}]",,['triple negatives']
56,SA216,MT1106,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1106'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour--From Alberta', 'EXTERNAL Sample ID ': 'MT1106'}]",,['triple negatives']
57,SA217,GT278,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT278'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour--From Alberta', 'EXTERNAL Sample ID ': 'GT278'}]",,['triple negatives']
58,SA218,CT040,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT040'}, {'Note': '', 'Tissue/Cell line': 'Breast Tumour--From Alberta', 'EXTERNAL Sample ID ': 'CT040'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT040'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT040'}]",,['triple negatives']
59,SA219,GT031,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT031'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT031'}, {'Note': 'plate based library comparison', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT031'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT031'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT031'}]",,['triple negatives']
60,SA220,CT063,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT063'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT063'}, {'Note': 'plate based library comparison', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT063'}]",,['triple negatives']
61,SA221,MT0904,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0904'}, {'Note': 'T/N pair genotyped at CTAG', 'Tissue/Cell line': 'Breast tumor', 'EXTERNAL Sample ID ': 'MT0904'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0904'}]",,"['exome capture-triple negatives', 'triple negatives']"
62,SA222,MT0443,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0443'}, {'Note': 'T/N pair genotyped at CTAG', 'Tissue/Cell line': 'Breast tumor', 'EXTERNAL Sample ID ': 'MT0443'}]",,['triple negatives']
63,SA223,GT048,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT048'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT048'}, {'Note': 'plate based library comparison', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT048'}]",,['triple negatives']
64,SA224,MT0511,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0511'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0511  '}, {'Note': 'plate based library comparison', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0511  '}]",,['triple negatives']
65,SA225,MT1034,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1034'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1034'}, {'Note': 'plate based library comparison', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1034'}]",,['triple negatives']
66,SA226,MT0390,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0390'}, {'Note': 'T/N pair genotyped at CTAG', 'Tissue/Cell line': 'Breast tumor', 'EXTERNAL Sample ID ': 'MT0390'}]",,['triple negatives']
67,SA227,MT0918,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0918'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0918'}, {'Note': 'plate based library comparison', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0918'}]",,['triple negatives']
68,SA228,MT0398,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0398'}, {'Note': 'T/N pair genotyped at CTAG', 'Tissue/Cell line': 'Breast tumor', 'EXTERNAL Sample ID ': 'MT0398'}]",,['triple negatives']
69,SA229,MT1339,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1339'}, {'Note': 'T/N pair genotyped at CTAG', 'Tissue/Cell line': 'Breast tumor', 'EXTERNAL Sample ID ': 'MT1339'}]",,['triple negatives']
70,SA230,MT0675,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0675'}, {'Note': 'T/N pair genotyped at CTAG', 'Tissue/Cell line': 'Breast tumor', 'EXTERNAL Sample ID ': 'MT0675'}]",,['triple negatives']
71,SA231,MT0457,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0457'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0457'}]",,['triple negatives']
72,SA232,MT0365,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0365'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0365'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0365'}]",,['triple negatives']
73,SA233,GT125,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT125'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT125'}]",,['triple negatives']
74,SA234,MT0124,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0124'}, {'Note': 'T/N pair genotyped at CTAG', 'Tissue/Cell line': 'Breast tumor', 'EXTERNAL Sample ID ': 'MT0124'}]",,['triple negatives']
75,SA235,MT0382,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0382'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0382'}]",,['triple negatives']
76,SA236,MT0541,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0541'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0541'}]",,['triple negatives']
77,SA237,GT091,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT091'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT091'}]",,['triple negatives']
78,SA238,BM01-20,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'BM01-20'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'BM01-20'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'BM01-20'}]",,['triple negatives']
79,SA239,MT0240,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0240'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0240'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0240'}]",,['triple negatives']
80,SA335,,MCF10A DNA 1.2 ug/ul,"[{'Note': '', 'Tissue/Cell line': 'MCF10A DNA 1.2 ug/ul', 'EXTERNAL Sample ID ': ''}, {'Note': '', 'Tissue/Cell line': 'MCF10A RNA 2.5 ug/ul', 'EXTERNAL Sample ID ': ''}]",,['']
81,SA029N,TTR0001002,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'TTR0001002'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'TTR0001002'}]",,['triple negatives']
82,SA065N,IDC - TTR0001050,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'IDC - TTR0001050'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'TTR0001050'}]",,['triple negatives']
83,SA068N,IDC - TTR0001044,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'IDC - TTR0001044'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'TTR0001008 '}]",,['triple negatives']
84,SA073N,IDC - TTR0001011,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'IDC - TTR0001011'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': ' TTR0001011'}]",,['triple negatives']
85,SA076N,IDC - TTR0001047,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'IDC - TTR0001047'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'TTR0001047'}]",,['triple negatives']
86,SA085N,Camb 83133,Buffy coat,"[{'Note': 'on HOLD-inadequate amoutn of T DNA', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'Camb 83133'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'BB98.0032'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'BB98.0032PE'}]",on HOLD-inadequate amoutn of T DNA,['triple negatives']
87,SA089N,TTR0001009,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'TTR0001009'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'TTR0001009'}]",,['triple negatives']
88,SA090N,TTR0001010,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'TTR0001010'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'TTR0001010'}]",,['triple negatives']
89,SA342,NCIH1975_PARENTAL,NSCLC*,"[{'Note': 'Cell lines from Pfizer', 'Tissue/Cell line': 'NSCLC*', 'EXTERNAL Sample ID ': 'NCIH1975_PARENTAL'}, {'Note': 'mouse contamination/HS2350', 'Tissue/Cell line': 'NSCLC*', 'EXTERNAL Sample ID ': 'NCIH1975_PARENTAL'}]",Cell lines from Pfizer,['resistant/met cell lines']
90,SA356,A1005 1-198,Cell lines from Park lab in Montreal,"[{'Note': ""mouse tumors can't be used on human exome chips"", 'Tissue/Cell line': 'Cell lines from Park lab in Montreal', 'EXTERNAL Sample ID ': 'A1005 1-198'}, {'Note': 'released for seq Sep 2010', 'Tissue/Cell line': 'Cell lines from Park lab in Montreal', 'EXTERNAL Sample ID ': 'A1005 1-198'}]",mouse tumors can't be used on human exome chips,['resistant/met cell lines']
91,SA357,A1471 1-220,Cell lines from Park lab in Montreal,"[{'Note': ""mouse tumors can't be used on human exome chips"", 'Tissue/Cell line': 'Cell lines from Park lab in Montreal', 'EXTERNAL Sample ID ': 'A1471 1-220'}, {'Note': 'released for seq Sep 2010', 'Tissue/Cell line': 'Cell lines from Park lab in Montreal', 'EXTERNAL Sample ID ': 'A1471 1-220'}]",mouse tumors can't be used on human exome chips,['resistant/met cell lines']
92,SA358,5154 G8885,Cell lines from Park lab in Montreal,"[{'Note': ""mouse tumors can't be used on human exome chips"", 'Tissue/Cell line': 'Cell lines from Park lab in Montreal', 'EXTERNAL Sample ID ': '5154 G8885'}, {'Note': 'released for seq Sep 2010', 'Tissue/Cell line': 'Cell lines from Park lab in Montreal', 'EXTERNAL Sample ID ': '5154 G8885'}]",mouse tumors can't be used on human exome chips,['resistant/met cell lines']
93,SA359,5156-4,Cell lines from Park lab in Montreal,"[{'Note': ""mouse tumors can't be used on human exome chips"", 'Tissue/Cell line': 'Cell lines from Park lab in Montreal', 'EXTERNAL Sample ID ': '5156-4'}, {'Note': 'released for seq Sep 2010', 'Tissue/Cell line': 'Cell lines from Park lab in Montreal', 'EXTERNAL Sample ID ': '5156-4'}]",mouse tumors can't be used on human exome chips,['resistant/met cell lines']
94,SA218N,CT040,Buffy coat-from Alberta,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat-from Alberta', 'EXTERNAL Sample ID ': 'CT040'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'CT040_BC'}]",,['triple negatives']
95,SA221N,MT0904,Buffy coat,"[{'Note': 'T/N pair genotyped at CTAG', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0904'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0904'}]",T/N pair genotyped at CTAG,"['exome capture-triple negatives', 'triple negatives']"
96,SA219N,GT031,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'GT031'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'GT031_BC'}]",,['triple negatives']
97,SA289,CT079,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT079'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT079 '}]",,['triple negatives']
98,SA291,GT191,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT191'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT191 '}]",,['triple negatives']
99,SA298,MT0041,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0041'}, {'Note': 'removed from the queue', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0041'}, {'Note': 'Low quality RNA - removed from the queue', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0041'}]",,['triple negatives']
100,SA280,MT0052,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0052'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0052 '}]",,['triple negatives']
101,SA292,MT0056,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0056'}, {'Note': 'removed from the queue', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0056'}, {'Note': 'Low quality RNA - removed from the queue', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0056'}]",,['triple negatives']
102,SA287,MT0091,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0091'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'MT0091'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0091'}]",,['triple negatives']
103,SA293,MT0112,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0112'}, {'Note': 'retrieved from GSC due to insuficient amounts', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0112'}]",,['triple negatives']
104,SA283,MT0549,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0549'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0549'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0549'}]",,['triple negatives']
105,SA275,MT0836,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0836'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0836'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0836'}]",,['triple negatives']
106,SA296,MT1144,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1144'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1144 E1'}]",,['triple negatives']
107,SA295,MT1191,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1191'}, {'Note': 'removed from the queue', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1191'}, {'Note': 'Low quality RNA - removed from the queue', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1191'}]",,['triple negatives']
108,SA286,MT1382,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1382'}, {'Note': 'Top up needed - submitted on Jan 04, 2013', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1382 '}]",,['triple negatives']
109,SA281,MT1394,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1394'}, {'Note': 'removed from the queue', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1394'}, {'Note': 'Low quality RNA - removed from the queue', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1394'}]",,['triple negatives']
110,SA288,MT1466,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1466'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1466 E1'}]",,['triple negatives']
111,SA300,MT1660,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1660'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1660'}, {'Note': 'new submission (Oct 18, 2011) - poor quality seq - short inserts & high level of reagent seq observed (old lib ID A06696)', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1660'}]",,['triple negatives']
112,SA285,MT1804,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1804'}, {'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1804 E1'}]",,['triple negatives']
113,SA276,MT2031,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT2031'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'MT2031'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT2031'}]",,['triple negatives']
114,SA289N,CT079,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'CT079'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'CT079-BC'}]",,['triple negatives']
115,SA291N,GT191,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'GT191'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'GT191-BC'}]",,['triple negatives']
116,SA298N,MT0041,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0041'}, {'Note': 'removed from the queue', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0041'}]",,['triple negatives']
117,SA280N,MT0052,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0052'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0052-BC'}]",,['triple negatives']
118,SA292N,MT0056,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0056'}, {'Note': 'removed from the queue', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0056'}]",,['triple negatives']
119,SA287N,MT0091,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0091'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'MT0091_BC'}]",,['triple negatives']
120,SA293N,MT0112,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0112'}, {'Note': 'retrieved from GSC due to insuficient amounts', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0112_BC'}]",,['triple negatives']
121,SA283N,MT0549,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0549'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0549_BC'}]",,['triple negatives']
122,SA275N,MT0836,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0836'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT0836_BC'}]",,['triple negatives']
123,SA296N,GVM0278,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'GVM0278'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'GVM0278_BC'}]",,['triple negatives']
124,SA295N,GVM0315,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'GVM0315'}, {'Note': 'removed from the queue', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'GVM0315'}]",,['triple negatives']
125,SA286N,MT1382,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT1382'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT1382-BC'}]",,['triple negatives']
126,SA281N,MT1394,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT1394'}, {'Note': 'removed from the queue', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT1394'}]",,['triple negatives']
127,SA288N,MT1466,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT1466'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT1466 _BC'}]",,['triple negatives']
128,SA285N,MT1804,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT1804'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT1804 _BC'}]",,['triple negatives']
129,SA276N,MT2031,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT2031'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'MT2031_BC'}]",,['triple negatives']
130,SA279,MT1579,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1579'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'MT1579'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1579'}]",,['triple negatives']
131,SA279N,MT1579,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'MT1579'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'MT1579_BC'}]",,['triple negatives']
132,SA389,,HEK293T+vector-72h,"[{'Note': 'pool of A08401 (H3K4me3 of SA389) and A08402 (H3K27me3 of SA389)', 'Tissue/Cell line': 'HEK293T+vector-72h', 'EXTERNAL Sample ID ': ''}, {'Note': 'pool of A08404 (H3K36me3 of SA389) and A08405 (Input DNA Control of SA389)', 'Tissue/Cell line': 'HEK293T+vector-72h', 'EXTERNAL Sample ID ': ''}, {'Note': '', 'Tissue/Cell line': 'HEK293T+vector-72h', 'EXTERNAL Sample ID ': ''}]",pool of A08401 (H3K4me3 of SA389) and A08402 (H3K27me3 of SA389),['ezh2']
133,SA390,,HEK293T+EZH2wt-72h,"[{'Note': 'pool of A08406 (H3K4me3 of SA390) and A08407 (H3K27me3 of SA390)', 'Tissue/Cell line': 'HEK293T+EZH2wt-72h', 'EXTERNAL Sample ID ': ''}, {'Note': 'pool of A08409 (H3K36me3 of SA390) and A08410 (Input DNA Control of SA390)', 'Tissue/Cell line': 'HEK293T+EZH2wt-72h', 'EXTERNAL Sample ID ': ''}, {'Note': '', 'Tissue/Cell line': 'HEK293T+EZH2wt-72h', 'EXTERNAL Sample ID ': ''}]",pool of A08406 (H3K4me3 of SA390) and A08407 (H3K27me3 of SA390),['ezh2']
134,SA391,,HEK293T+EZH2Y641N-72h,"[{'Note': 'pool of A08411 (H3K4me3 of SA391) and A08412 (H3K27me3 of SA391)', 'Tissue/Cell line': 'HEK293T+EZH2Y641N-72h', 'EXTERNAL Sample ID ': ''}, {'Note': 'pool of A08414 (H3K36me3 of SA391) and A08415 (Input DNA Control of SA391)', 'Tissue/Cell line': 'HEK293T+EZH2Y641N-72h', 'EXTERNAL Sample ID ': ''}, {'Note': '', 'Tissue/Cell line': 'HEK293T+EZH2Y641N-72h', 'EXTERNAL Sample ID ': ''}]",pool of A08411 (H3K4me3 of SA391) and A08412 (H3K27me3 of SA391),['ezh2']
135,SA392,,HEK293T+EZH2Y641F-72h,"[{'Note': 'A08416 (H3K4me3 of SA392) and A08417 (H3K27me3 of SA392)', 'Tissue/Cell line': 'HEK293T+EZH2Y641F-72h', 'EXTERNAL Sample ID ': ''}, {'Note': 'pool of A08419 (H3K36me3 of SA392) and A08420 (Input DNA Control of SA392)', 'Tissue/Cell line': 'HEK293T+EZH2Y641F-72h', 'EXTERNAL Sample ID ': ''}, {'Note': '', 'Tissue/Cell line': 'HEK293T+EZH2Y641F-72h', 'EXTERNAL Sample ID ': ''}]",A08416 (H3K4me3 of SA392) and A08417 (H3K27me3 of SA392),['ezh2']
136,SA095N,VBA0082,Buffy coat,"[{'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'VBA0082'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'VBA0082-PE'}]",,['triple negatives']
137,SA417,MT3062,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3062'}, {'Note': 'v3 chemistry for Illumina in place', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3062'}]",,['triple negatives']
138,SA418,MT2621,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT2621'}, {'Note': 'v3 chemistry for Illumina in place', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT2621'}]",,['triple negatives']
139,SA423,MT2988,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT2988'}, {'Note': 'v3 chemistry for Illumina in place', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT2988'}]",,['triple negatives']
140,SA425,MT2932,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT2932'}, {'Note': 'v3 chemistry for Illumina in place', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT2932'}]",,['triple negatives']
141,SA494X4,X0459-XXX2,Xenograft breast tumor-generation 4,"[{'Note': '', 'Tissue/Cell line': 'Xenograft breast tumor-generation 4', 'EXTERNAL Sample ID ': 'X0459-XXX2'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0459'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
142,SA496X2,X0532-41,Xenograft breast tumor-generation 2,"[{'Note': 'SNP analysis at GSC suggest a swap with SA499X5', 'Tissue/Cell line': 'Xenograft breast tumor-generation 2', 'EXTERNAL Sample ID ': 'X0532-41'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0532'}]",SNP analysis at GSC suggest a swap with SA499X5,"['breast cancer xeno/genome evolution', 'xenograft']"
143,SA499X5,X0616-XXXX1,Xenograft breast tumor-generation 5,"[{'Note': 'SNP analysis at GSC suggest a swap with SA496X2', 'Tissue/Cell line': 'Xenograft breast tumor-generation 5', 'EXTERNAL Sample ID ': 'X0616-XXXX1'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0616'}]",SNP analysis at GSC suggest a swap with SA496X2,"['breast cancer xeno/genome evolution', 'xenograft']"
144,SA500X3,X0654-222,Xenograft breast tumor-generation 3,"[{'Note': '', 'Tissue/Cell line': 'Xenograft breast tumor-generation 3', 'EXTERNAL Sample ID ': 'X0654-222'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0654'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
145,SA530X2,VBA0663,Xenograft breast tumor-generation 2,"[{'Note': 'PCR free - plate based library prep -had to do 8 cycle of PCR', 'Tissue/Cell line': 'Xenograft breast tumor-generation 2', 'EXTERNAL Sample ID ': 'VBA0663'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0663'}]",PCR free - plate based library prep -had to do 8 cycle of PCR,"['breast cancer xeno/genome evolution', 'xenograft']"
146,SA531X1,VBA0699,Xenograft breast tumor-generation 1,"[{'Note': '', 'Tissue/Cell line': 'Xenograft breast tumor-generation 1', 'EXTERNAL Sample ID ': 'VBA0699'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0699'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
147,SA532X3,CBX002,Xenograft breast tumor-generation 3,"[{'Note': '', 'Tissue/Cell line': 'Xenograft breast tumor-generation 3', 'EXTERNAL Sample ID ': 'CBX002'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX002'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
148,SA534X1,CBX008,Xenograft breast tumor-generation 1,"[{'Note': '', 'Tissue/Cell line': 'Xenograft breast tumor-generation 1', 'EXTERNAL Sample ID ': 'CBX008'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX008'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
149,SA535X1,CBX011,Xenograft breast tumor-generation 1,"[{'Note': '', 'Tissue/Cell line': 'Xenograft breast tumor-generation 1', 'EXTERNAL Sample ID ': 'CBX011'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX011'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
150,SA541N,STG201_BC_Cambridge,Buffy coat,"[{'Note': 'PCR free - plate based library prep', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'STG201_BC_Cambridge'}, {'Note': '', 'Tissue/Cell line': 'Buffy coat', 'EXTERNAL Sample ID ': 'STG201_BC_Cambridge'}]",PCR free - plate based library prep,['breast cancer xeno/genome evolution']
151,SA541X0,STG201_X0_Cambridge,Xenograft breast tumor-generation 1,"[{'Note': 'PCR free - plate based library prep', 'Tissue/Cell line': 'Xenograft breast tumor-generation 1', 'EXTERNAL Sample ID ': 'STG201_X0_Cambridge'}, {'Note': 'slightly more than 15% threshold mouse contamination observed in the first lane', 'Tissue/Cell line': 'Xenograft Breast tumor-generation 1', 'EXTERNAL Sample ID ': 'STG201_X0_Cambridge'}]",PCR free - plate based library prep,['breast cancer xeno/genome evolution']
152,SA501X5,X0662-5,Xenograft breast tumor-generation 5,"[{'Note': '', 'Tissue/Cell line': 'Xenograft breast tumor-generation 5', 'EXTERNAL Sample ID ': 'X0662-5'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0662'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
153,SA576X1,CBX021,Xenograft Breast tumor-generation 1,"[{'Note': '', 'Tissue/Cell line': 'Xenograft Breast tumor-generation 1', 'EXTERNAL Sample ID ': 'CBX021'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX021'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
154,SA654,MT3442,,"[{'Note': 'v4 chemistry', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'MT3442'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3442'}]",v4 chemistry,['triple negatives']
155,SA655,MT486,,"[{'Note': 'v4 chemistry', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'MT486'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT486'}]",v4 chemistry,['triple negatives']
156,SA274,GT847,,"[{'Note': 'v4 chemistry', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GT847'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT847'}]",v4 chemistry,['triple negatives']
157,SA665,MT4386,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT4386'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT4386'}]",,['triple negatives']
158,SA394,GT472,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT472'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT472'}]",,['triple negatives']
159,SA395,MT0596,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0596'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT0596'}]",,['triple negatives']
160,SA666,CT202,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT202'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT202'}]",,['triple negatives']
161,SA667,CT266,TN- Breast Tumor,"[{'Note': ""very low SNP concordance with the match normal. No other match with anything else sequnced at GSC. Internal Aparicio lab records also doesn't show a mistmatch during processing. Most likey an original mismatch- STR was NOT performed on this case."", 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT266'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'CT266'}]",very low SNP concordance with the match normal. No other match with anything else sequnced at GSC. Internal Aparicio lab records also doesn't show a mistmatch during processing. Most likey an original mismatch- STR was NOT performed on this case.,['triple negatives']
162,SA668,GT618,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT618'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'GT618'}]",,['triple negatives']
163,SA669,MT1228,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1228'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1228'}]",,['triple negatives']
164,SA671,MT2873,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT2873'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT2873'}]",,['triple negatives']
165,SA672,MT3142,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3142'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3142'}]",,['triple negatives']
166,SA673,MT3318,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3318'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3318'}]",,['triple negatives']
167,SA674,MT3435,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3435'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3435'}]",,['triple negatives']
168,SA675,MT3516,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3516'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3516'}]",,['triple negatives']
169,SA676,MT3538,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3538'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3538'}]",,['triple negatives']
170,SA677,MT3588,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3588'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3588'}]",,['triple negatives']
171,SA678,MT3840,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3840'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT3840'}]",,['triple negatives']
172,SA679,MT4149,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT4149'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT4149'}]",,['triple negatives']
173,SA680,MT4195,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT4195'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT4195'}]",,['triple negatives']
174,SA681,MT4425,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT4425'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT4425'}]",,['triple negatives']
175,SA682,MT4440,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT4440'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT4440'}]",,['triple negatives']
176,SA683,MT4584,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT4584'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT4584'}]",,['triple negatives']
177,SA398,MT1350,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1350'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1350'}]",,['triple negatives']
178,SA272,MT1386,TN- Breast Tumor,"[{'Note': '', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1386'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': 'TN- Breast Tumor', 'EXTERNAL Sample ID ': 'MT1386'}]",,['triple negatives']
179,SA604X4,CBX038,,"[{'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX038'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX038'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
180,SA606X1,VBA0799,,"[{'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0799'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0799'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
181,SA607_3X2,CBX013,,"[{'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX013'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX013'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
182,SA608X1,CBX015,,"[{'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX015'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX015'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
183,SA609X2,CBX028,,"[{'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX028'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX028'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
184,SA610X1,CBX029,,"[{'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX029'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'CBX029'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
185,SA611X1,VBA0766,,"[{'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0766'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0766'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
186,SA684X1,VBA0804,,"[{'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0804'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0804'}]",,"['breast cancer xeno/genome evolution', 'xenograft']"
187,SA501X10A,VBA0662,,"[{'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VBA0662'}, {'Note': 'v4 chemistry', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': ''}]",,['breast cancer xeno/genome evolution']
188,SA820B,VOA2451b,Omentum,"[{'Note': '', 'Tissue/Cell line': 'Omentum', 'EXTERNAL Sample ID ': 'VOA2451b'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '01383'}]",,['intartumoral heterogeneity']
189,SA820C,VOA2451c,Omentum,"[{'Note': '', 'Tissue/Cell line': 'Omentum', 'EXTERNAL Sample ID ': 'VOA2451c'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '01383'}]",,['intartumoral heterogeneity']
190,SA820E,VOA2451e,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA2451e'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '01383'}]",,['intartumoral heterogeneity']
191,SA820G,VOA2451g,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA2451g'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '01383'}]",,['intartumoral heterogeneity']
192,SA820J,VOA2451j,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA2451j'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '01383'}]",,['intartumoral heterogeneity']
193,SA821B,VOA3293b,Groin,"[{'Note': '', 'Tissue/Cell line': 'Groin', 'EXTERNAL Sample ID ': 'VOA3293b'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '02650'}]",,['intartumoral heterogeneity']
194,SA821C,VOA3293c,Omentum,"[{'Note': '', 'Tissue/Cell line': 'Omentum', 'EXTERNAL Sample ID ': 'VOA3293c'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '02650'}, {'Note': '', 'Tissue/Cell line': 'Omentum', 'EXTERNAL Sample ID ': 'VOA3293c'}]",,['intartumoral heterogeneity']
195,SA821E,VOA3293e,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA3293e'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '02650'}]",,['intartumoral heterogeneity']
196,SA821G,VOA3293g,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA3293g'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '02650'}]",,['intartumoral heterogeneity']
197,SA821J,VOA3293j,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA3293j'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '02650'}]",,['intartumoral heterogeneity']
198,SA822C,VOA3981c,Omentum,"[{'Note': '', 'Tissue/Cell line': 'Omentum', 'EXTERNAL Sample ID ': 'VOA3981c'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '02946'}, {'Note': '', 'Tissue/Cell line': 'Omentum', 'EXTERNAL Sample ID ': 'VOA3981c'}]",,['intartumoral heterogeneity']
199,SA822E,VOA3981e,Bladder,"[{'Note': '', 'Tissue/Cell line': 'Bladder', 'EXTERNAL Sample ID ': 'VOA3981e'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '02946'}, {'Note': '', 'Tissue/Cell line': 'Bladder', 'EXTERNAL Sample ID ': 'VOA3981e'}]",,['intartumoral heterogeneity']
200,SA822G,VOA3981g,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA3981g'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '02946'}]",,['intartumoral heterogeneity']
201,SA822I,VOA3981i,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA3981i'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '02946'}]",,['intartumoral heterogeneity']
202,SA822K,VOA3981k,Cul-de-sac,"[{'Note': '', 'Tissue/Cell line': 'Cul-de-sac', 'EXTERNAL Sample ID ': 'VOA3981k'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '02946'}, {'Note': '', 'Tissue/Cell line': 'Cul-de-sac', 'EXTERNAL Sample ID ': 'VOA3981k'}]",,['intartumoral heterogeneity']
203,SA823N,VOA4224BC,Blood,"[{'Note': '', 'Tissue/Cell line': 'Blood', 'EXTERNAL Sample ID ': 'VOA4224BC'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA4224BC'}]",,"['intartumoral heterogeneity', 'ith']"
204,SA823A,VOA4309a,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA4309a'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03159'}, {'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA4309a'}]",,['intartumoral heterogeneity']
205,SA823C,VOA4309c,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA4309c'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03159'}]",,['intartumoral heterogeneity']
206,SA823E,VOA4309e,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA4309e'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03159'}]",,['intartumoral heterogeneity']
207,SA823H,VOA4309h,Cul-de-sac,"[{'Note': '', 'Tissue/Cell line': 'Cul-de-sac', 'EXTERNAL Sample ID ': 'VOA4309h'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03159'}]",,['intartumoral heterogeneity']
208,SA823I,VOA4309i,Small Intestine,"[{'Note': '', 'Tissue/Cell line': 'Small Intestine', 'EXTERNAL Sample ID ': 'VOA4309i'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03159'}, {'Note': '', 'Tissue/Cell line': 'Small Intestine', 'EXTERNAL Sample ID ': 'VOA4309i'}]",,['intartumoral heterogeneity']
209,SA824B,VOA4723b,Omentum,"[{'Note': '', 'Tissue/Cell line': 'Omentum', 'EXTERNAL Sample ID ': 'VOA4723b'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03380'}]",,['intartumoral heterogeneity']
210,SA824D,VOA4723d,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA4723d'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03380'}]",,['intartumoral heterogeneity']
211,SA824E,VOA4723e,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA4723e'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03380'}]",,['intartumoral heterogeneity']
212,SA824G,VOA4723g,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA4723g'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03380'}]",,['intartumoral heterogeneity']
213,SA824J,VOA4723j,Peritoneum,"[{'Note': '', 'Tissue/Cell line': 'Peritoneum', 'EXTERNAL Sample ID ': 'VOA4723j'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03380'}]",,['intartumoral heterogeneity']
214,SA825A,VOA4778a,Omentum,"[{'Note': '', 'Tissue/Cell line': 'Omentum', 'EXTERNAL Sample ID ': 'VOA4778a'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03478'}]",,['intartumoral heterogeneity']
215,SA825D,VOA4778d,Omentum,"[{'Note': '', 'Tissue/Cell line': 'Omentum', 'EXTERNAL Sample ID ': 'VOA4778d'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03478'}]",,['intartumoral heterogeneity']
216,SA825E,VOA4778e,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA4778e'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03478'}]",,['intartumoral heterogeneity']
217,SA825G,VOA4778g,Ovary,"[{'Note': '', 'Tissue/Cell line': 'Ovary', 'EXTERNAL Sample ID ': 'VOA4778g'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03478'}]",,['intartumoral heterogeneity']
218,SA825J,VOA4778j,Omentum,"[{'Note': '', 'Tissue/Cell line': 'Omentum', 'EXTERNAL Sample ID ': 'VOA4778j'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': '03478'}]",,['intartumoral heterogeneity']
219,SA992,X1963,Xenograft,"[{'Note': 'Tumour from McGill for Xenograft group', 'Tissue/Cell line': 'Xenograft', 'EXTERNAL Sample ID ': 'X1963'}, {'Note': 'Tumour from McGill for Xenograft group', 'Tissue/Cell line': 'Xenograft (x1963)', 'EXTERNAL Sample ID ': 'GCRC1963'}]",Tumour from McGill for Xenograft group,"['intartumoral heterogeneity', 'single cell project']"
220,SA997T," V15-1905L-3T  #1,#2 +#1",GCRC1905 Primary tumor,"[{'Note': 'Tumour from McGill for Xenograft group', 'Tissue/Cell line': 'GCRC1905 Primary tumor', 'EXTERNAL Sample ID ': '\xc2\xa0V15-1905L-3T\xc2\xa0 #1,#2 +#1'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': ' V15-1905L-3T  #1,#2 +#1'}]",Tumour from McGill for Xenograft group,['metaplastic brca']
221,SA998T,V14-1840-1T #1,GCRC1840 Primary tumor,"[{'Note': 'Tumour from McGill for Xenograft group', 'Tissue/Cell line': 'GCRC1840 Primary tumor', 'EXTERNAL Sample ID ': 'V14-1840-1T #1'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V14-1840-1T #1'}]",Tumour from McGill for Xenograft group,['metaplastic brca']
222,SA1016T,V15-1868-7T #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V15-1868-7T #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V15-1868-7T #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
223,SA1017T,J2015-1876,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J2015-1876'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J2015-1876'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
224,SA1018T,N14-1856-3M ,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'N14-1856-3M '}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'N14-1856-3M '}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
225,SA1019T,J2015-1971,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J2015-1971'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J2015-1971'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
226,SA1020T,J2015-1991,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J2015-1991'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J2015-1991'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
227,SA1021T,V2015-1882-7T #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V2015-1882-7T #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V2015-1882-7T #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
228,SA1022T,"V2015-1886-14T Reg2 #1, #2",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V2015-1886-14T Reg2 #1, #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V2015-1886-14T Reg2 #1, #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
229,SA1023T,V15-1915-1T #1,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V15-1915-1T #1'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V15-1915-1T #1'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
230,SA1024T,"V15-1939R-3T #1 ,#3",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V15-1939R-3T #1 ,#3'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V15-1939R-3T #1 ,#3'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
231,SA1025T,"V2015-1863-1T #1, #2",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V2015-1863-1T #1, #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V2015-1863-1T #1, #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
232,SA1026T,V16-2001R-1T #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V16-2001R-1T #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V16-2001R-1T'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
233,SA1027T,"V14-1828-1T #1,#2",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V14-1828-1T #1,#2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V14-1828-1T #1,#2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
234,SA1028T,V14-1834-1T #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V14-1834-1T #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V14-1834-1T #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
235,SA1029T,V13-1715-2T ,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V13-1715-2T '}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V13-1715-1T(primary combine #1,2 from 20170330, #1,2,6 from 20170407)'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
236,SA1030T,V13-1738-1T ,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V13-1738-1T '}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V13-1738-1T '}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
237,SA1030LM,V13-1738-LM ,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V13-1738-LM\xc2\xa0'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V13-1738-LM\xc3\x8a'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
238,SA1033T,N15-1945-3M,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'N15-1945-3M'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'N15-1945-3M'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
239,SA1035T,V2016-2006R-2T,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V2016-2006R-2T'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V2016-2006R-2T'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
240,SA1036T,V16-2007-2T #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V16-2007-2T #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V16-2007-2T #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
241,SA1037T,"J16-2029-T (T-684 A1, #2)",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J16-2029-T (T-684 A1, #2)'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J16-2029-T (T-684 A1, #2)'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
242,SA1038T,"V2016-2047-1T  July 29, 2016",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V2016-2047-1T  July 29, 2016'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V2016-2047-1T  July 29, 2016'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
243,SA1040T,"J16-2061-T (T-706, #3)",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J16-2061-T (T-706, #3)'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J16-2061T-T (T706, #3)'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
244,SA1042T,V16-2080-1T #1,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V16-2080-1T #1'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V16-2080-1T #1'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
245,SA1016X3_3L,GCRC1868T-P3-3L PDX #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1868T-P3-3L PDX #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1868T-P3-3L PDX #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
246,SA1017X1_4L,GCRC1876T-P1-4L #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1876T-P1-4L #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1876T-P1-4L #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
247,SA1018X1_7R,GCRC1856 P1-7R #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1856 P1-7R #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1856 P1-7R #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
248,SA1019X1_1L,"GCRC1971S-P1-1L PDX #1, #2",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1971S-P1-1L PDX #1, #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1971S-P1-1L PDX #1, #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
249,SA1020X1_2L,"GCRC1991T-P1-2L PDX #1,#2",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1991T-P1-2L PDX #1,#2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1991T-P1-2L PDX #1, #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
250,SA1021X2_1L,GCRC1882T4-P2-1L PDX#1 ,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1882T4-P2-1L PDX#1 '}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1882T4-P2-1L PDX#1 '}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
251,SA1022X1_3L,GCRC1886T2-P1-3L  PDX ,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1886T2-P1-3L  PDX '}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1886T2-P1-3L  PDX '}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
252,SA1023X1_2L,GCRC1915T-P1-2L  PDX #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1915T-P1-2L  PDX #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1915T-P1-2L  PDX #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
253,SA1024X1_1L,GCRC1939T-P1-1L PDX #1,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1939T-P1-1L PDX #1'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1939T-P1-1L PDX #1'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
254,SA1025X1_2R,GCRC1863T-P1-2R #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1863T-P1-2R #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1863T-P1-2R #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
255,SA1026X1_4R,GCRC2001T P1-4R,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2001T P1-4R'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2001T P1-4R'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
256,SA1027X1_1L,"GCRC1828T-P1-1L #1, #2",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1828T-P1-1L #1, #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1828T-P1-1L #1, #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
257,SA1028X3_3L,GCRC1834T-P3-3L PDX #1/#2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1834T-P3-3L PDX #1/#2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1834T-P3-3L PDX #1/#2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
258,SA1029X2_14L,GCRC1715 P2-14L#3,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1715 P2-14L#3'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1715 P2-14L#3'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
259,SA1030X2_17L,GCRC1738T-P2-17L#1,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1738T-P2-17L#1'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1738T-P2-17L#1'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
260,SA1031X1_1R,GCRC1944Br-P1-1R PDX #1,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1944Br-P1-1R PDX #1'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1944Br-P1-1R PDX #1'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
261,SA1032X1_2R,GCRC1979T-P1-2R PDX #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1979T-P1-2R PDX #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1979T-P1-2R PDX #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
262,SA1033X1_2R,GCRC1945Br-P1-2R PDX #1,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1945Br-P1-2R PDX #1'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1945Br-P1-2R PDX #1'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
263,SA1035X1_8L,GCRC2006T P1-8L,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2006T P1-8L'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2006T P1-8L'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
264,SA1036X2_2R,GCRC2007 P2-2R #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2007 P2-2R #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2007 P2-2R #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
265,SA1037X1_2L,GCRC2029 P1-2L#2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2029 P1-2L#2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2029 P1-2L#2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
266,SA1038X1_2L,GCRC2047 P1-2L #1,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2047 P1-2L #1'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2047 P1-2L #1'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
267,SA1039X1_3L,GCRC2054 P1-3L #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2054 P1-3L #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2054 P1-3L #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
268,SA1040X1_1L,GCRC2061 P1-1L #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2061 P1-1L #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2061 P1-1L #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
269,SA1041X2_1,GCRC2076 P2-1 - frag 1*#2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2076 P2-1 - frag 1*#2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2076 P2-1 - frag 1*#2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
270,SA1042X1_2L,GCRC2080 P1-2L #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2080 P1-2L #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2080 P1-2L #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
271,SA1043X1_2L,GCRC2089 P1-2L#3,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2089 P1-2L#3'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC2089 P1-2L#3'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
272,SA920T,V2013-1735-1T #1,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V2013-1735-1T #1'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V2013-1735-1T #1'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
273,SA992T,J2015-1963,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J2015-1963'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J2015-1963'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
274,SA993T,J15-1924-LN (T-561 A1),,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J15-1924-LN (T-561 A1)'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'J2015-1924'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
275,SA994T,"V15-1851-1T #1,#2",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V15-1851-1T #1,#2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'V15-1851-1T #1,#2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
276,SA995T,N15-1887-5M ,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'N15-1887-5M\xc2\xa0'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'N15-1887-5M\xc3\x8a'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
277,SA920X2_23R,GCRC1735T-P2-23R PDX #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1735T-P2-23R PDX #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1735T-P2-23R PDX #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
278,SA992X1_4R,"GCRC1963T-P1-4R PDX#1,#2",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1963T-P1-4R PDX#1,#2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1963T-P1-4R PDX#1,#2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
279,SA993X2_5R,GCRC1924LN-P2-5R  PDX,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1924LN-P2-5R  PDX'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1924LN-P2-5R  PDX'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
280,SA994X2_3L,"GCRC1851T-P2-3L PDX #1, #2",,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1851T-P2-3L PDX #1, #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1851T-P2-3L PDX #1, #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
281,SA995X1_5R,GCRC1887Br P1-5R 1/2 #2,,"[{'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1887Br P1-5R 1/2 #2'}, {'Note': 'Dr. Morag pays half on seq.', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'GCRC1887Br P1-5R 1/2 #2'}]",Dr. Morag pays half on seq.,"['genome-hiseqx', 'metaplastic brca']"
282,SA1046,VOA5576,,"[{'Note': 'A1', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA5576'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA5576'}]",A1,['ith immune']
283,SA1047A,VOA6428A,,"[{'Note': 'B1', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA6428A'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA6428A'}]",B1,['ith immune']
284,SA1047B,VOA6428B,,"[{'Note': 'C1', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA6428B'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA6428B'}]",C1,['ith immune']
285,SA1047C,VOA6428C,,"[{'Note': 'D1', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA6428C'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA6428C'}]",D1,['ith immune']
286,SA1047D,VOA6428D,,"[{'Note': 'E1', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA6428D'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA6428D'}]",E1,['ith immune']
287,SA1049A,VOA7640A,,"[{'Note': 'G1', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7640A'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7640A'}]",G1,['ith immune']
288,SA1050A,VOA7648A,,"[{'Note': 'B2', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7648A'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7648A'}]",B2,['ith immune']
289,SA1050B,VOA7648B,,"[{'Note': 'C2', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7648B'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7648B'}]",C2,['ith immune']
290,SA1050C,VOA7648C,,"[{'Note': 'D2', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7648C'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7648C'}]",D2,['ith immune']
291,SA1050D,VOA7648D,,"[{'Note': 'E2', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7648D'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7648D'}]",E2,['ith immune']
292,SA1050E,VOA7648E,,"[{'Note': 'F2', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7648E'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7648E'}]",F2,['ith immune']
293,SA1050F,VOA7648F,,"[{'Note': 'G2', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7648F'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7648F'}]",G2,['ith immune']
294,SA1051A,VOA7652A,,"[{'Note': 'H2', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7652A'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7652A'}]",H2,['ith immune']
295,SA1051E,VOA7652E,,"[{'Note': 'D3', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7652E'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7652E'}]",D3,['ith immune']
296,SA1052A,VOA7668A,,"[{'Note': 'G3', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7668A'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7668A'}]",G3,['ith immune']
297,SA1052D,VOA7668D,,"[{'Note': 'B4', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7668D'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7668D'}]",B4,['ith immune']
298,SA1052E,VOA7668E,,"[{'Note': 'C4', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7668E'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7668E'}]",C4,['ith immune']
299,SA1053A,VOA7685A,,"[{'Note': 'H4', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7685A'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7685A'}]",H4,['ith immune']
300,SA1053B,VOA7685B,,"[{'Note': 'A5', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7685B'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7685B'}]",A5,['ith immune']
301,SA1053C,VOA7685C,,"[{'Note': 'B5', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7685C'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7685C'}]",B5,['ith immune']
302,SA1053D,VOA7685D,,"[{'Note': 'C5', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7685D'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7685D'}]",C5,['ith immune']
303,SA1053F,VOA7685F,,"[{'Note': 'E5', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7685F'}, {'Note': '', 'Tissue/Cell line': '', 'EXTERNAL Sample ID ': 'VOA7685F'}]",E5,['ith immune']
1077,SA608T,CBX015,,,,[u'breast cancer xeno/genome evolution']
1026,SA272N,MT1386_BC,Buffy coat,,,[u'triple negatives']
839,SA426N,MT3042_BC,Buffy coat,,,[u'triple negatives']
425,SA015-4,184-hTERT L9 passage 11,hTert cell line,,,[u'htert methylation']
429,SA015-4,184-hTERT L9 passage 11,hTert cell line,,,[u'htert methylation']
333,SA209N,MT1177,Buffy coat-from Alberta,,,[u'triple negatives']
926,SA650,184hTert NIH CLK 1/4 Probe 0.5uM,,,,[u'takeda-japan-splicing project']
952,SA658N,Her2-6,Buffy coat,,,[u'her2 breast cancer']
1364,SA852-R1,231_scramSix2_2,MDA-MB-231,,,[u'takeda-japan-splicing project']
796,SA576T,CBX021,Breast tumor,,,[u'breast cancer xeno/genome evolution']
348,SA337,GTL16_903R_CLONE R1,gstric carcinoma,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
349,SA337,GTL16_903R_CLONE R1,gstric carcinoma,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
346,SA336,GTL16_PARENTAL,gstric carcinoma,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
347,SA336,GTL16_PARENTAL,gstric carcinoma,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
1773,SA1033N,"N2015-1945 01BC Sept03, 2015",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1784,SA1036N,"V16-2007-1N,2N",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1067,SA608N,CBX015,,,,[u'breast cancer xeno/genome evolution']
350,SA338,GTL16_903R_CLONE R3,gstric carcinoma,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
351,SA338,GTL16_903R_CLONE R3,gstric carcinoma,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
27,SA003-H3K79me3,,HCT116,,,['']
669,SA495N,VBA0509-CD3+, Pleural effusion ,,,[u'breast cancer xeno/genome evolution']
1397,SA870,B18 CX5461 10^-8 2D #6,HCT116,,,[u'genomic instability and mutational signatures of cancer']
1398,SA871,B18 CX5461 10^-8 2D #8,HCT116,,,[u'genomic instability and mutational signatures of cancer']
726,SA529,HCT116-GSK3-72h 5uM,HCT116,,,[u'takeda-japan-splicing project']
1400,SA873,B18 PDS 3,HCT116,,,[u'genomic instability and mutational signatures of cancer']
1401,SA874,B18 PDS 6,HCT116,,,[u'genomic instability and mutational signatures of cancer']
914,SA638,184hTert L41 10uM,,,,[u'takeda-japan-splicing project']
951,SA657N,Her2-4,Buffy coat,,,[u'her2 breast cancer']
1404,SA877,B18 PDS 24,HCT116,,,[u'genomic instability and mutational signatures of cancer']
1405,SA878,V2013-1784-1T,,,,[u'metaplastic brca']
1406,SA879,GCRC1784T-P1-7L,,,,[u'metaplastic brca']
1299,SA820N,VOA4463BC,Blood,,,[u'intartumoral heterogeneity']
1130,SA723T-1B,VBA0834,,,,[u'intartumoral heterogeneity']
1517,SA820H,01383,,,,[u'intartumoral heterogeneity']
1518,SA820I,01383,,,,[u'intartumoral heterogeneity']
1912,SA1070N,VBA0887,,D7,D7,[u'biopsy series']
1592,SA979,B18 Control #24,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1591,SA978,B18 Control #20,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1882,SA1070T,VBA0887,,F3,F3,[u'biopsy series']
1584,SA971,WT PDS 2D 10^-6 #4,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1583,SA970,WT PDS 2D 10^-6 #3,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1586,SA973,WT PDS 2D 10^-6 #7,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1585,SA972,WT PDS 2D 10^-6 #6,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1588,SA975,B18 Control #11,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1587,SA974,B18 Control #6,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1590,SA977,B18 Control #16,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1589,SA976,B18 Control #14,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
884,SA404N,VBA0467,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
1455,SA574X2,VBA0743,,,,[u'xenograft']
1877,SA1068_2T,CBX076,,A3,A3,[u'biopsy series']
1072,SA604_3T,CBX038,,,,[u'breast cancer xeno/genome evolution']
1099,SA718T-2A,VBA0773,,,,[u'intartumoral heterogeneity']
1910,SA1068N,CBX074,,B7,B7,[u'biopsy series']
1866,SA1068T,CBX074,,F1,F1,[u'biopsy series']
1807,DAH184,VOA223C,,,,[u'fold back inversion']
1493,SA938,VOA4846 CL,,,,[u'intartumoral heterogeneity']
1884,SA1063T,CBX050,,H3,H3,[u'biopsy series']
1722,SA1020N,J2015-1991 Buffy Coat,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1117,SA721T-1C,VBA0790,,,,[u'intartumoral heterogeneity']
1833,SA1051F,VOA7652F,,E3,E3,[u'ith immune']
615,SA429N,VBA0569-BC,Buffy coat,,,[u'breast cancer xeno/genome evolution']
1341,SA832-R1,HCT116_T3-5.0,HCT116,,,[u'takeda-japan-splicing project']
758,SA542X0,STG195_X0_Cambridge,Xenograft breast tumor-generation 1,,,[u'breast cancer xeno/genome evolution']
1269,SA805,HCT116 BRCA-/-,HCT116 BRCA-/-,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1268,SA804,HCT116 BRCA-/-,HCT116 BRCA-/-,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1271,SA807,HCT116 BRCA-/-,HCT116 BRCA-/-,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1270,SA806,HCT116 BRCA-/-,HCT116 BRCA-/-,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1265,SA801,HCT116 WT,HCT116 WT,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1264,SA800,HCT116 WT,HCT116 WT,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1267,SA803,HCT116 BRCA-/-,HCT116 BRCA-/-,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1266,SA802,HCT116 BRCA-/-,HCT116 BRCA-/-,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1119,SA721T-2B,VBA0790,,,,[u'intartumoral heterogeneity']
1905,SA1063N,CBX050,,E6,E6,[u'biopsy series']
1273,SA809,HCT116 WT,HCT116 WT,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1272,SA808,HCT116 WT,HCT116 WT,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1956,SA1086,VBA1804,,,,[u'single cell project']
1223,SA759,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1222,SA758,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
747,SA536N,STG143N,normal Breast,,,[u'breast cancer xeno/genome evolution']
220,SA207, 9-08 'B' basal, primary mammary epithelial cells,,,[u'\xa0primary hmec']
219,SA206, 9-08 'A' luminal, primary mammary epithelial cells,,,[u'\xa0primary hmec']
218,SA205,"Mll5 -/- LSK sorted BM (35,000 cells)","Bone marrow, MLL5 -/- LSK sorted BM",,,[u'mll5']
217,SA204,"Mll5 +/+ LSK sorted BM (57,000 cells)","Bone marrow, MLL5+/+ LSK sorted BM",,,[u'mll5']
216,SA203,81777 (MB-AD-0149),Breast Tumour,Top priorityto finish metabric paper,Top priorityto finish metabric paper,[u'metabric']
215,SA202,VBA0504,Saliva,To detect contaminants in human saliva,To detect contaminants in human saliva,[u'saliva']
214,SA201,VBA0512,Saliva,To detect contaminants in human saliva,To detect contaminants in human saliva,[u'saliva']
213,SA200,VBA0514,Saliva,To detect contaminants in human saliva,To detect contaminants in human saliva,[u'saliva']
744,SA535N,CBX011,Buffy coat,,,[u'breast cancer xeno/genome evolution']
868,SA588N,GT1366_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
966,SA535-X0011-2312,X0011-2312,xenograft breast tumor,,,[u'breast cancer xeno/genome evolution']
1924,SA1082,,,,,[u'genomic instability and mutational signatures of cancer']
450,SA231N,MT0457,Buffy coat,,,[u'triple negatives']
1014,SA675N,MT3516_BC,Buffy coat,,,[u'triple negatives']
955,SA661N,Her2-14,Buffy coat,,,[u'her2 breast cancer']
872,SA592N,MT27_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
1481,SA926,A52408 ,AML,,,[u'single cell project']
1383,SA858-R2,231_T836_24h_0.5_3,MDA-MB-231,,,[u'takeda-japan-splicing project']
546,SA271N,MT0113,Buffy coat,,,[u'triple negatives']
960,SA532-X0002-3533,X0002-3533,xenograft breast tumor,pool prior to capture - 6x pool per capture - Agilent All Exon V5 + UTR,pool prior to capture - 6x pool per capture - Agilent All Exon V5 + UTR,[u'breast cancer xeno/genome evolution']
1380,SA858-R1,231_T836_24h_0.5_2,MDA-MB-231,,,[u'takeda-japan-splicing project']
1080,SA609T,CBX028,,,,[u'breast cancer xeno/genome evolution']
336,SA212N,MT0578,Buffy coat-from Alberta,,,[u'triple negatives']
1141,SA728,HCT116-WT-cx5461 10^-7,HCT116-WT-Caldas lab-p29, with FASTQ ($75/10files), with FASTQ ($75/10files),[u'genomic instability and mutational signatures of cancer']
1142,SA729,HCT116-B18-no drug ,HCT116-B18_p53-/-_Caldas lab-p29, with FASTQ ($75/10files), with FASTQ ($75/10files),[u'genomic instability and mutational signatures of cancer']
308,SA098N,TB02.0281,Buffy coat,,,[u'triple negatives']
1477,SA922,OV2295-(2),ovarian cell line,,,[u'single cell project']
1138,SA725,HCT116-WT-no drug ,HCT116-WT-Caldas lab-p29, with FASTQ ($75/10files), with FASTQ ($75/10files),[u'genomic instability and mutational signatures of cancer']
1139,SA726,HCT116-WT-cx5461 10^-9,HCT116-WT-Caldas lab-p29, with FASTQ ($75/10files), with FASTQ ($75/10files),[u'genomic instability and mutational signatures of cancer']
1140,SA727,HCT116-WT-cx5461 10^-8,HCT116-WT-Caldas lab-p29, with FASTQ ($75/10files), with FASTQ ($75/10files),[u'genomic instability and mutational signatures of cancer']
678,SA500,VBA0654,Her2(+) - Breast tumor,,,[u'breast cancer xeno/genome evolution']
680,SA501,VBA0662,TN-Breast tumor,,,[u'breast cancer xeno/genome evolution']
699,SA502,hTer-T3-6hctrl,184-hTeRT,,,[u'takeda-japan-splicing project']
700,SA503,hTer-T3-6h 0.5uMCLKi,184-hTeRT,,,[u'takeda-japan-splicing project']
701,SA504,hTer-T3-6hctrl 1uMCLKi,184-hTeRT,,,[u'takeda-japan-splicing project']
702,SA505,hTer-T3-6hctrl 5uMCLKi,184-hTeRT,,,[u'takeda-japan-splicing project']
703,SA506,Takeda-1-iPSC#1,iPSC,,,[u'takeda-japan-splicing project']
119,SA055,IDC - TTR0001024,Breast Tumour,,,[u'triple negatives']
1025,SA398N,MT1350_BC,Buffy coat,,,[u'triple negatives']
706,SA509,Takeda-4-NPC#1,NPC,,,[u'takeda-japan-splicing project']
1476,SA921,TOV2295,ovarian cell line,,,[u'single cell project']
1399,SA872,B18 PDS 1,HCT116,,,[u'genomic instability and mutational signatures of cancer']
419,SA226N,MT0390,Buffy coat,T/N pair genotyped at CTAG,T/N pair genotyped at CTAG,[u'triple negatives']
828,SA290,MT1584 E1,TN- Breast Tumor,,,[u'triple negatives']
959,hTERT-SC 07/2014,,,constructed single cell library - submitted by Carl Han's group,constructed single cell library - submitted by Carl Han's group,['']
1118,SA721T-2A,VBA0790,,,,[u'intartumoral heterogeneity']
509,SA294,MT0656,TN- Breast Tumor,"removed due to inadequate amount of normal DNA availabe, determined after QC at GSC","removed due to inadequate amount of normal DNA availabe, determined after QC at GSC",[u'triple negatives']
384,SA355,M24MET R m10,Melanoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
385,SA355,M24MET R m10,Melanoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
511,SA297,MT0937,TN- Breast Tumor,,,[u'triple negatives']
500,SA299,GT470,TN- Breast Tumor,,,[u'triple negatives']
578,SA299,GT470,TN- Breast Tumor,,,[u'triple negatives']
596,SA299,GT470,TN- Breast Tumor,,,[u'triple negatives']
661,SA299,GT470,TN- Breast Tumor,,,[u'triple negatives']
161,SA081,IDC - TTR0001069,Breast Tumour,,,[u'triple negatives ']
162,SA081,IDC - TTR0001069,Breast Tumour,,,[u'triple negatives ']
1285,SA811N,Her2-34,Blood,,,[u'her2 breast cancer']
1402,SA875,B18 PDS 11,HCT116,,,[u'genomic instability and mutational signatures of cancer']
1403,SA876,B18 PDS 2d 12,HCT116,,,[u'genomic instability and mutational signatures of cancer']
1114,SA721N,VBA0790,,,,[u'intartumoral heterogeneity']
370,SA348,786-0 Parental m31,Renal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
371,SA348,786-0 Parental m31,Renal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
1515,SA820F,01383,,,,[u'intartumoral heterogeneity']
890,SA614,HCT116 L41 0.5uM,,,,[u'takeda-japan-splicing project']
891,SA615,HCT116 L41 1uM,,,,[u'takeda-japan-splicing project']
892,SA616,HCT116 L41 5uM,,,,[u'takeda-japan-splicing project']
1898,SA576_2T,CBX024,,F5,F5,[u'biopsy series']
875,SA595N,MT3662_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
859,SA599,MT4475,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1158,SA599,MT4475,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
858,SA598,MT4469,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1157,SA598,MT4469,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
857,SA597,MT4444,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1156,SA597,MT4444,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
856,SA596,MT4428,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1155,SA596,MT4428,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
855,SA595,MT3662,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1154,SA595,MT3662,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
854,SA594,MT3402,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
853,SA593,MT3352,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1153,SA593,MT3352,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
852,SA592,MT27,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1152,SA592,MT27,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
851,SA591,MT1525,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1151,SA591,MT1525,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
850,SA590,MT1023,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1150,SA590,MT1023,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
478,SA377,Takeda-9Colon,Transverse Colon,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
477,SA376,Takeda-5Colon,Transverse Colon,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
476,SA375,Takeda-R9Duodenum,Duodenum,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
475,SA374,Takeda-2Duodenum,Duodenum,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
474,SA373,Takeda-9Adipose,Brown adipose tissue,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
473,SA372,Takeda-3Adipose,Brown adipose tissue,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
472,SA371,Takeda-12Liver,liver,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
471,SA370,Takeda-4Liver,liver,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
1070,SA604T,CBX038,,,,[u'breast cancer xeno/genome evolution']
480,SA379,Takeda-9Ileum,Ileum,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
479,SA378,Takeda-5 Ileum,Ileum,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
1473,SA918X1,VBA0812,,,,[u'xenograft']
789,SA571,HCT116-CLK1+2+3+4-25siRNA,HCT116,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
788,SA570,HCT116-CLK1+2+4siRNA,HCT116,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
791,SA573,HCT116-LF2K,HCT116,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
790,SA572,HCT116-NT3siRNA,HCT116,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
1031,SA684,,,SA_ID issued but sample was never used for  sequencing,SA_ID issued but sample was never used for  sequencing,['']
807,SA579,VBA0733,luminal breast tumor,,,[u'ffpe vs frozen tissue performance on miseq']
354,SA340,GTL16_903R_CLONE S5,gstric carcinoma,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
355,SA340,GTL16_903R_CLONE S5,gstric carcinoma,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
1053,SA706,HCT116_S2WT_P19,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1908,SA1066N,CBX062,,H6,H6,[u'biopsy series']
1475,SA920X4,VBA1735,,,,[u'xenograft']
356,SA341,GTL16_903R_CLONE F3,gstric carcinoma,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
357,SA341,GTL16_903R_CLONE F3,gstric carcinoma,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
540,SA284N,MT0445,Buffy coat,,,[u'triple negatives']
732,SA531N,VBA0699,Buffy coat,,,[u'breast cancer xeno/genome evolution']
938,SA274N,GT847_BC,,v4 chemistry,v4 chemistry,[u'triple negatives']
366,SA346,786-0 SutR m17,Renal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
367,SA346,786-0 SutR m17,Renal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
191,SA096,VBA0290,TN- Breast Tumor,,,[u'triple negatives ']
192,SA096,VBA0290,TN- Breast Tumor,,,[u'triple negatives ']
421,SA229N,MT1339,Buffy coat,T/N pair genotyped at CTAG,T/N pair genotyped at CTAG,[u'triple negatives']
1639,SA1014,(-) control + E2,T47 breast cancer cell line,,,[u'ppp2r2a']
1640,SA1015,Salmon Sperm DNA control,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,['']
1637,SA1012,3x (#5+#6+#8) siPPP2R2A + E2,T47 breast cancer cell line,,,[u'ppp2r2a']
1638,SA1013,siNT + E2,T47 breast cancer cell line,,,[u'ppp2r2a']
1635,SA1010,#6 siPPP2R2A + E2,T47 breast cancer cell line,,,[u'ppp2r2a']
1636,SA1011,#8 siPPP2R2A + E2,T47 breast cancer cell line,,,[u'ppp2r2a']
1876,SA1062_2T,CBX041,,H2,H2,[u'biopsy series']
1893,SA1066T,CBX062,,A5,A5,[u'biopsy series']
1916,SA1074N,VBA1367,,H7,H7,[u'biopsy series']
305,SA094N,Camb 83233,Buffy coat,,,[u'triple negatives']
274,SA054N,TTR0001023,Buffy coat,,,[u'triple negatives']
311,SA101N,TB03.0088,Buffy coat,,,[u'triple negatives']
1020,SA681N,MT4425_BC,Buffy coat,,,[u'triple negatives']
739,SA533X1,CBX004,Xenograft breast tumor-generation 1,,,[u'breast cancer xeno/genome evolution']
1069,SA610N,CBX029,,,,[u'breast cancer xeno/genome evolution']
1452,SA533X2,CBX004,,,,[u'xenograft']
1865,SA722_3T,CBX066,,E1,E1,[u'biopsy series']
65,SA023 (rename as SA017),IDC - TTR0001003,DNA fr.hu breast tumour tissue ,,,[u'triple negatives']
340,SA216N,MT1106,Buffy coat-from Alberta,,,[u'triple negatives']
1137,SA724X5,VSA225,,,,[u'torsten lab_myxoid liposarcoma']
1852,SA1048N,VOA6733BC,,H5,H5,[u'ith immune']
1801,SA1043N,"J17-2089-N (T-774, #6)",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1358,SA849,siSRRM1 48hr,HCT116,,,[u'takeda-japan-splicing project']
1357,SA848,siNT 48hr,HCT116,,,[u'takeda-japan-splicing project']
1479,SA924,A48073 ,AML,,,[u'single cell project']
1480,SA925,A44891 ,AML,,,[u'single cell project']
352,SA339,GTL16_903R_CLONE S4,gstric carcinoma,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
353,SA339,GTL16_903R_CLONE S4,gstric carcinoma,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
1478,SA923,A32061 ,AML,,,[u'single cell project']
1610,SA920,GCGC1735,Xenograft (x1963),Tumour from McGill for Xenograft group,Tumour from McGill for Xenograft group,[u'intartumoral heterogeneity']
832,SA409N,MT3120_BC,Buffy coat,,,[u'triple negatives']
1350,SA841,HCT116_KHCB19-10.0_Tak,HCT116,,,[u'takeda-japan-splicing project']
1349,SA840,HCT116_KHCB19-5.0_Tak,HCT116,,,[u'takeda-japan-splicing project']
1352,SA843,HCT116_KHCB19-5.0_Tak,HCT116,,,[u'takeda-japan-splicing project']
1351,SA842,HCT116_KHCB19-1.0_Tak,HCT116,,,[u'takeda-japan-splicing project']
1354,SA845,siNT 48hr,HCT116,,,[u'takeda-japan-splicing project']
1353,SA844,HCT116_KHCB19-10.0_Tak,HCT116,,,[u'takeda-japan-splicing project']
1356,SA847,siSRRM2 48hr,HCT116,,,[u'takeda-japan-splicing project']
774,SA556,SKBR3-CDK12 siRNA (611)-3,SKBR3 ,,,[u'takeda-japan-splicing project']
31,SA004-H3K79me3,,HCT116,,,['']
1527,SA821H,02650,,,,[u'intartumoral heterogeneity']
841,SA428N,MT3038_BC,Buffy coat,,,[u'triple negatives']
806,SA533-3T,CBX004,Breast tumor- 3rd biopsy,,,[u'breast cancer xeno/genome evolution']
1761,SA995N,"N2015-1887 01BC Feb26, 2015",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1873,SA575_3T,CBX027,,E2,E2,[u'biopsy series']
294,SA075N,IDC - TTR0001027,frozen normal,,,[u'triple negatives']
819,SA412,MT3341,TN- Breast Tumor,,,[u'triple negatives']
735,SA532N,CBX002,Buffy coat,,,[u'breast cancer xeno/genome evolution']
53,SA016,VBA0038 buffy coat gDNA,DNA fr.hu blood- buffy coat,library on hold,library on hold,[u'lobular breast']
1382,SA859-R1,231_T092_24h_1.5_2,MDA-MB-231,,,[u'takeda-japan-splicing project']
759,SA429X5,VBA0569-XenoG5,Xenograft breast tumor-generation 5,,,[u'breast cancer xeno/genome evolution']
299,SA084N,Camb 82658,Buffy coat,,,[u'triple negatives']
35,SA007,,HCT116,,,[u'sirna screen']
616,SA429X2,VBA0569-XenoG2,Xenograft breast tumor-generation 2,,,[u'breast cancer xeno/genome evolution']
1441,SA429X3,VBA0569,,,,[u'xenograft']
776,SA558,SKBR3-untransfected-2,SKBR3 ,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
1010,SA671N,MT2873_BC,Buffy coat,,,[u'triple negatives']
1106,SA719T-2B,VBA0774,,,,[u'intartumoral heterogeneity']
1105,SA719T-2A,VBA0774,,,,[u'intartumoral heterogeneity']
1022,SA682N,MT4440_BC,Buffy coat,,,[u'triple negatives']
838,SA424N,MT3315_BC,Buffy coat,,,[u'triple negatives']
623,SA435,184-hTeRT-L9-T1 100 nM,184-hTeRT,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
876,SA596N,MT4428_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
423,SA234N,MT0124,Buffy coat,T/N pair genotyped at CTAG,T/N pair genotyped at CTAG,[u'triple negatives']
905,SA629,HCT116 NIH CLK 1/4 Probe 0.5uM,,,,[u'takeda-japan-splicing project']
904,SA628,HCT116 NIH CLK 1/4 Probe 0.2uM,,,,[u'takeda-japan-splicing project']
901,SA625,HCT116 Z110128700 1uM,,,,[u'takeda-japan-splicing project']
900,SA624,HCT116 Z110128700 0.5uM,,,,[u'takeda-japan-splicing project']
903,SA627,HCT116 Z110128700 10uM,,,,[u'takeda-japan-splicing project']
902,SA626,HCT116 Z110128700 5uM,,,,[u'takeda-japan-splicing project']
897,SA621,HCT116 KH-CB19 5uM,,,,[u'takeda-japan-splicing project']
896,SA620,HCT116 KH-CB19 1uM,,,,[u'takeda-japan-splicing project']
899,SA623,HCT116 Z110128700 0.2uM,,"replacement sample had to be sent to GSC - submitted on Dec 19, 2014 - to be fast tracked for an additional cost of $957.78.","replacement sample had to be sent to GSC - submitted on Dec 19, 2014 - to be fast tracked for an additional cost of $957.78.",[u'takeda-japan-splicing project']
898,SA622,HCT116 KH-CB19 10uM,,,,[u'takeda-japan-splicing project']
1329,SA825N,VOA4955BC,Blood,,,[u'intartumoral heterogeneity']
1252,SA788,SKBR3_scramblesi_1,SKBR3,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'takeda-japan-splicing project']
1253,SA789,SKBR3_KUTRsi_1,SKBR3,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'takeda-japan-splicing project']
1566,SA825I,03478,,,,[u'intartumoral heterogeneity']
1565,SA825H,03478,,,,[u'intartumoral heterogeneity']
1246,SA782,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1563,SA825F,03478,,,,[u'intartumoral heterogeneity']
418,SA222N,MT0443,Buffy coat,T/N pair genotyped at CTAG,T/N pair genotyped at CTAG,[u'triple negatives']
1245,SA781,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
534,SA299N,GVM0383,Buffy coat,,,[u'triple negatives']
590,SA299N,GVM0383,Buffy coat,,,[u'triple negatives']
1559,SA825B,03478,,,,[u'intartumoral heterogeneity']
704,SA507,Takeda-2-iPSC#2,iPSC,,,[u'takeda-japan-splicing project']
1249,SA785,SKBR3_CDK12si_Dharmacon_1,SKBR3,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'takeda-japan-splicing project']
298,SA083N,IDC - TTR0001073,Buffy coat,,,[u'triple negatives']
291,SA072N,IDC - TTR0001008,Buffy coat,,,[u'triple negatives']
1372,SA854-R2,231_KUTRsi_3,MDA-MB-231,,,[u'takeda-japan-splicing project']
175,SA088,TTR0001067,Breast Tumour,,,[u'rare breast cancer subtypes']
176,SA088,TTR0001067,Breast Tumour,,,[u'rare breast cancer subtypes']
1289,SA815N,Her2-5,Blood,,,[u'her2 breast cancer']
1370,SA854-R1,231_KUTRsi_2,MDA-MB-231,,,[u'takeda-japan-splicing project']
1430,SA901-R2,231_CDK13_5449si_1,,,,[u'cdk13 (charge back to greg)']
1429,SA901-R1,231_CDK13_5449si_1,,,,[u'cdk13 (charge back to greg)']
1058,SA711,HCT116_S2B83_P40,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1057,SA710,HCT116_S2WT_P40,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1060,SA713,HCT116_S2B46_P42,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1059,SA712,HCT116_S2B18_P41,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1062,SA715,HCT116_S2WT_P64,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1061,SA714,HCT116_S2B83_P60,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1064,SA717,HCT116_S2B18_P69,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1063,SA716,HCT116_S2B46_P69,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1805,DAH168,VOA139A,,,,[u'fold back inversion']
927,SA651,184hTert NIH CLK 1/4 Probe 1uM,,,,[u'takeda-japan-splicing project']
1219,SA755,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
929,SA653,184hTert NIH CLK 1/4 Probe 10uM,,,,[u'takeda-japan-splicing project']
942,SA656,Her2-3,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
943,SA657,Her2-4,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
617,SA430,,mouse genome,2 separate libraries arel made to use as the reference genome,2 separate libraries arel made to use as the reference genome,[u'breast cancer xeno/genome evolution']
618,SA430,,mouse genome,2 separate libraries arel made to use as the reference genome,2 separate libraries arel made to use as the reference genome,[u'breast cancer xeno/genome evolution']
619,SA431,184-hTeRT-L2-DMSO,184-hTeRT,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
620,SA432,184-hTeRT-L2-T1 100nM,184-hTeRT,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
974,SA405N,TTR1014,TN- normal tissue,T/N mismatch - under investigation at GSC,T/N mismatch - under investigation at GSC,[u'triple negatives']
622,SA434,184-hTeRT-L9-DMSO,184-hTeRT,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
28,SA003-H3K9me3,,HCT116,,,['']
624,SA436,184-hTeRT-L9-T3 100 nM,184-hTeRT,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
625,SA437,HCT116-WT-ATCC-DMSO,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
626,SA438,HCT116-WT-ATCC-T1 100nM,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
627,SA439,HCT116-WT-ATCC-T3 100nM,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
1897,SA1057_2T,CBX010,,E5,E5,[u'biopsy series']
1899,SA1063_2T,CBX055,,G5,G5,[u'biopsy series']
1482,SA927,A53007,AML,,,[u'single cell project']
339,SA215N,C951,Buffy coat-from Alberta,,,[u'triple negatives']
1287,SA813N,Her2-32,Blood,,,[u'her2 breast cancer']
125,SA061 renamed as SA055,IDC - TTR0001024,Breast Tumour,,,[u'triple negatives']
24,SA002 or SA016,VBA0038 buffy coat gDNA,,,,['']
731,SA531,VBA0699,Her2 (+) -Breast tumor,,,[u'breast cancer xeno/genome evolution']
681,SA501N,VBA0662-SAL/10982,Saliva,,,[u'breast cancer xeno/genome evolution']
63,SA021,,CAPAN-1,,,[u'sirna screen']
1809,DAH208A,VOA445D1,,,,[u'fold back inversion']
743,SA535,CBX011,TN-Breast tumor,,,[u'breast cancer xeno/genome evolution']
740,SA534,CBX008,Her2(+)-Breast tumor,,,[u'breast cancer xeno/genome evolution']
749,SA537,HCT116-WT-ATCC-T3-6hctrl,HCT116,biological replicates for the previous CLKi experiment (SA464-SA470),biological replicates for the previous CLKi experiment (SA464-SA470),[u'takeda-japan-splicing project']
746,SA536,STG143 T,ER(+)-Breast tumor,,,[u'breast cancer xeno/genome evolution']
531,SA239N,MT0240,Buffy coat,,,[u'triple negatives']
589,SA239N,MT0240,Buffy coat,,,[u'triple negatives']
718,SA521,hTert-CDK12iRNA,184-hTeRT,,,[u'takeda-japan-splicing project']
1887,SA1062T,CBX037,,C4,C4,[u'biopsy series']
1764,SA1023N,"V2015-1915 01BC April13, 2015",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1373,SA855-R1,231_scramSi_2,MDA-MB-231,,,[u'takeda-japan-splicing project']
1374,SA855-R2,231_scramSi_3,MDA-MB-231,,,[u'takeda-japan-splicing project']
793,SA575T,CBX016,Breast tumor,,,[u'breast cancer xeno/genome evolution']
1339,SA831-R1,HCT116_T3-1.0,HCT116,,,[u'takeda-japan-splicing project']
315,SA106N,TB05.0712,Buffy coat,,,[u'triple negatives']
1749,SA1018N,N2018-1856- BC,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
794,SA575N,CBX016,Normal,,,[u'breast cancer xeno/genome evolution']
1713,SA993N,J2015-1924 Buffy Coat,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1136,SA724T,VSA225,,,,[u'torsten lab_myxoid liposarcoma']
1707,SA997X1_6L,GCRC1905T-P1-6L PDX #2,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'metaplastic brca']
1904,SA1062N,CBX037,,D6,D6,[u'biopsy series']
1858,SA1054,184-hTERT-22 clone ID 83.86,184 hTERT,,,['']
1859,SA1055,184-hTERT-22 clone ID 112.109,184 hTERT,,,['']
129,SA064,IDC - TTR0001049,Breast Tumour,,,[u'triple negatives']
130,SA064,IDC - TTR0001049,Breast Tumour,,,[u'triple negatives']
38,SA010,VBA0038,RNA fr. Human pleural effusion cells,LBC metastasis,LBC metastasis,['']
1033,SA686,DLD1_S1Bn_P21,DLD,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
633,SA445,HCT116-WT-BV-T3 100nM,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
632,SA444,HCT116-WT-BV-T1 100nM,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
635,SA447,HCT116-BRCA2-/-18-T1 100nM,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
634,SA446,HCT116-BRCA2-/-18 DMSO,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
629,SA441,HCT116-WT-CC-T1 100nM,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
628,SA440,HCT116-WT-CC-DMSO,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
631,SA443,HCT116-WT-BV-DMSO,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
630,SA442,HCT116-WT-CC-T3 100nM,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
1731,SA1027N,"V2014-1828 LeukosOct14,2014",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
637,SA449,HCT116-BRCA2-/-46 DMSO,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
636,SA448,HCT116-BRCA2-/-18-T3 100nM,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
1004,SA666N,CT202_BC,Buffy coat,,,[u'triple negatives']
834,SA412N,MT3341_BC,Buffy coat,,,[u'triple negatives']
869,SA589N,GT154_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
734,SA532,CBX002,Her2(+)-Breast tumor,,,[u'breast cancer xeno/genome evolution']
1416,SA889,siSRSF4-4,HCT116-WT,,,[u'takeda-japan-splicing project']
1415,SA888,siSRSF4-2,HCT116-WT,,,[u'takeda-japan-splicing project']
32,SA004-H3K9me3,,HCT116,,,['']
1412,SA885,siSRSF1-3,HCT116-WT,,,[u'takeda-japan-splicing project']
1411,SA884,siSRSF1-2,HCT116-WT,,,[u'takeda-japan-splicing project']
1414,SA887,siKHDRBS1-4,HCT116-WT,,,[u'takeda-japan-splicing project']
1413,SA886,siKHDRBS1-1,HCT116-WT,,,[u'takeda-japan-splicing project']
1408,SA881,GCRC1784T P3-6R ,,,,[u'metaplastic brca']
1407,SA880,GCRC1784T P1-8L,,,,[u'metaplastic brca']
1410,SA883,siSRSF1-1,HCT116-WT,,,[u'takeda-japan-splicing project']
1409,SA882,GCRC1784T-P3-4L ,,,,[u'metaplastic brca']
267,SA018N,TTR0001005,Buffy coat,,,[u'triple negatives']
1581,SA968,WT PDS 2D #1,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1582,SA969,WT PDS 2D 10^-6 #2,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1842,SA1052H,VOA7668H,,F4,F4,[u'ith immune']
121,SA057 renamed as SA051,IDC - TTR0001012,Breast Tumour,,,[u'triple negatives']
1843,SA1052J,VOA7668J,,G4,G4,[u'ith immune']
1575,SA962,HCT WT CX1 B7,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1576,SA963,HCT WT CX1 B9,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1573,SA960,HCT WT CTL 1 D6,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1574,SA961,HCT WT CTL1 E3,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1579,SA966,HCT WT CX1 C11,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1580,SA967,HCT WT CX1 D5,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1577,SA964,HCT WT CX1 B4,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1578,SA965,HCT WT CX1 B11,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
449,SA227N,MT0918,Buffy coat,,,[u'triple negatives']
1491,SA936,VOA2008BC,,,,[u'intartumoral heterogeneity']
455,SA237N,GT091,Buffy coat,,,[u'triple negatives']
1284,SA810N,Her2-28,Blood,,,[u'her2 breast cancer']
953,SA659N,Her2-9,Buffy coat,,,[u'her2 breast cancer']
124,SA060 renamed as SA054,IDC - TTR0001023,Breast Tumour,,,[u'triple negatives']
1808,DAH197,VOA336C,,,,[u'fold back inversion']
748,SA536X0,STG143X0,Xenograft breast tumor-generation 1,,,[u'breast cancer xeno/genome evolution']
816,SA407,MT3305,TN- Breast Tumor,,,[u'triple negatives']
1015,SA676N,MT3538_BC,Buffy coat,,,[u'triple negatives']
552,SA300N,GVM0630,Buffy coat,,,[u'triple negatives']
595,SA300N,GVM0630,Buffy coat,,,[u'triple negatives']
297,SA080N,IDC - TTR0001006,Buffy coat,,,[u'triple negatives']
272,SA052N,TTR0001013,Buffy coat,,,[u'triple negatives']
401,SA052N,TTR0001013,Buffy coat,,,[u'triple negatives']
290,SA071N,IDC - TTR0001007,Buffy coat,,,[u'triple negatives']
1440,SA909,184hTERT-L9_99.5_p#53,184hTERT-L9_99.5,,,[u'breast cancer xeno/genome evolution']
1280,SA816,Her2-13,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
1281,SA817,Her2-11,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
1278,SA814,Her2-26,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
1279,SA815,Her2-5,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
1276,SA812,Her2-15,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
1277,SA813,Her2-32,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
1274,SA810,Her2-28,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
1275,SA811,Her2-34,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
1282,SA818,Her2-2,FFPE- Her2 breast Tumor,"Not Sequence, not enough DNA","Not Sequence, not enough DNA",[u'her2 breast cancer']
1283,SA819,Her2-10,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
612,SA423N,MT2988,Buffy coat,v3 chemistry for Illumina in place,v3 chemistry for Illumina in place,[u'triple negatives']
1484,SA929,,,,,[u'single cell project']
309,SA099N,TB02.0300,Buffy coat,,,[u'triple negatives']
1212,SA748,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
840,SA427N,CT176_BC,Buffy coat,,,[u'triple negatives']
1210,SA746,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1211,SA747,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1035,SA688,DLD1_S1Bn_P28,DLD,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1875,SA1059_2T,CBX025,,G2,G2,[u'biopsy series']
1206,SA742,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1207,SA743,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1204,SA740,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1205,SA741,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
667,SA494N,VBA0459-CD3+, Pleural effusion ,,,[u'breast cancer xeno/genome evolution']
1470,SA914X5,CBX064,,,,[u'xenograft']
1068,SA609N,CBX028,,,,[u'breast cancer xeno/genome evolution']
1913,SA1071N,VBA0910,,E7,E7,[u'biopsy series']
1076,SA607_3T,CBX013,,,,[u'breast cancer xeno/genome evolution']
1520,SA821A,02650,,,,[u'intartumoral heterogeneity']
307,SA097N,TB02.0034,Buffy coat,,,[u'triple negatives']
1525,SA821F,02650,,,,[u'intartumoral heterogeneity']
1293,SA819N,Her2-10,Blood,,,[u'her2 breast cancer']
1523,SA821D,02650,,,,[u'intartumoral heterogeneity']
1907,SA1065N,CBX054,,G6,G6,[u'biopsy series']
1528,SA821I,02650,,,,[u'intartumoral heterogeneity']
1743,SA1030N,1738 Leukos,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1305,SA821N,VOA3507BC,Blood,,,[u'intartumoral heterogeneity']
1872,SA1063_3T,CBX056,,D2,D2,[u'biopsy series']
555,SA278N,GVM1015,Buffy coat,,,[u'triple negatives']
1870,SA1065T,CBX054,,B2,B2,[u'biopsy series']
1471,SA915X2,CBX075,,,,[u'xenograft']
950,SA656N,Her2-3,Buffy coat,,,[u'her2 breast cancer']
1135,SA724N,VSA225,,,,[u'torsten lab_myxoid liposarcoma']
207,SA104,TB03.0391,TN- Breast Tumor,,,[u'triple negatives ']
208,SA104,TB03.0391,TN- Breast Tumor,,,[u'triple negatives ']
209,SA105,TB04.0291,TN- Breast Tumor,,,[u'triple negatives ']
210,SA105,TB04.0291,TN- Breast Tumor,,,[u'triple negatives ']
211,SA106,TB05.0712,TN- Breast Tumor,,,[u'triple negatives ']
212,SA106,TB05.0712,TN- Breast Tumor,,,[u'triple negatives ']
199,SA100,TB03.0341,TN- Breast Tumor,,,[u'triple negatives ']
200,SA100,TB03.0341,TN- Breast Tumor,,,[u'triple negatives ']
201,SA101,TB03.0088,TN- Breast Tumor,,,[u'triple negatives ']
202,SA101,TB03.0088,TN- Breast Tumor,,,[u'triple negatives ']
203,SA102,BB98.0097,TN- Breast Tumor,,,[u'triple negatives ']
204,SA102,BB98.0097,TN- Breast Tumor,,,[u'triple negatives ']
205,SA102,BB98.0097,TN- Breast Tumor,,,[u'triple negatives ']
206,SA103,TB03.0524,TN- Breast Tumor,,,[u'triple negatives ']
133,SA066,IDC - TTR0001052,Breast Tumour,,,[u'triple negatives']
134,SA066,IDC - TTR0001052,Breast Tumour,,,[u'triple negatives']
675,SA498N,VBA0614-BC,Buffy coat,,,[u'breast cancer xeno/genome evolution']
310,SA100N,TB03.0341,Buffy coat,,,[u'triple negatives']
1391,SA864,B18 Control #9,HCT116,,,[u'genomic instability and mutational signatures of cancer']
821,SA420,MT2851,TN- Breast Tumor,,,[u'triple negatives']
1247,SA783,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1244,SA780,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
878,SA598N,MT4469_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
1851,SA1047N,VOA6565BC,,G5,G5,[u'ith immune']
1879,SA1057T,CBX005,,C3,C3,[u'biopsy series']
946,SA660,Her2-12,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
1560,SA825C,03478,,,,[u'intartumoral heterogeneity']
1864,SA575_2T,CBX020,,D1,D1,[u'biopsy series']
335,SA211N,GVM0108,Buffy coat-from Alberta,seq suggests possible mismatched pair,seq suggests possible mismatched pair,[u'triple negatives']
949,SA663,Her2-21,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
1251,SA787,SKBR3_CDK12si_Dharmacon_3,SKBR3,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'takeda-japan-splicing project']
848,SA588,GT1366,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1148,SA588,GT1366,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
849,SA589,GT154,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1149,SA589,GT154,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
677,SA499N,VBA0616-BC,Buffy coat,,,[u'breast cancer xeno/genome evolution']
1355,SA846,siSRRM1 48hr,HCT116,,,[u'takeda-japan-splicing project']
958,SA664,single cell project,30 single cells indexed and pooled - 184hTert and TOV2295,constructe library submitted for sequencing _v4 chemistry,constructe library submitted for sequencing _v4 chemistry,[u'single cell project']
1218,SA754,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
808,SA580,VBA0751,TN- Breast Tumor,,,[u'ffpe vs frozen tissue performance on miseq']
809,SA581,VBA0744,luminal breast tumor,,,[u'ffpe vs frozen tissue performance on miseq']
810,SA582,VBA0746,luminal breast tumor,,,[u'ffpe vs frozen tissue performance on miseq']
811,SA583,VBA0738,luminal breast tumor,,,[u'ffpe vs frozen tissue performance on miseq']
812,SA584,VBA0735,luminal breast tumor,,,[u'ffpe vs frozen tissue performance on miseq']
1221,SA757,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
847,SA586,CT223,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1147,SA586,CT223,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
947,SA661,Her2-14,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
426,SA361,184-hTERT C6 p13,hTert cell line,,,[u'htert methylation']
430,SA361,184-hTERT C6 p13,hTert cell line,,,[u'htert methylation']
427,SA362,184-hTERT L5 p13,hTert cell line,,,[u'htert methylation']
431,SA362,184-hTERT L5 p13,hTert cell line,,,[u'htert methylation']
1220,SA756,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
457,SA364,SKBR3 DMSO,mammary gland cell line,,,[u'miami lap r_cell lines']
459,SA364,SKBR3 DMSO,mammary gland cell line,,,[u'miami lap r_cell lines']
466,SA365,83242,Breast Tumour-from Cambridge,,,[u'metabric']
467,SA366,81765,Breast Tumour-from Cambridge,2nd lane was already running by the time the goal was adjusted for these cases,2nd lane was already running by the time the goal was adjusted for these cases,[u'metabric']
468,SA367,82586,Breast Tumour-from Cambridge,,,[u'metabric']
469,SA368,82668,Breast Tumour-from Cambridge,,,[u'metabric']
1215,SA751,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
663,SA029MET,TTR1002-met lymph node,Breast tumor lymph node metastasis,library construction using SPRI-TE platform,library construction using SPRI-TE platform,[u'triple negatives']
1850,SA1046N,VOA4995BC,,F5,F5,[u'ith immune']
1214,SA750,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
784,SA566,HCT116-CLK3siRNA,HCT116,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
785,SA567,HCT116-CLK4siRNA,HCT116,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
782,SA564,HCT116-CLK1siRNA,HCT116,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
783,SA565,HCT116-CLK2siRNA,HCT116,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
780,SA562,184htert-CDK12 siRNA (611)-2,184-hTert,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
1217,SA753,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
778,SA560,184htert-scramble siRNA-1,184-hTert,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
779,SA561,184htert-scramble siRNA-3,184-hTert,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
863,SA403,VBA0195,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1216,SA752,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
972,SA405,TTR1014,TN- Breast Tumor,T/N mismatch - all investigations (at GSC and internal) suggests mistmach between the content of the of DNA tubes in the lab. ,T/N mismatch - all investigations (at GSC and internal) suggests mistmach between the content of the of DNA tubes in the lab. ,[u'triple negatives']
1132,SA723T-2A,VBA0834,,,,[u'intartumoral heterogeneity']
786,SA568,HCT116-CLK1+2+3siRNA,HCT116,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
787,SA569,HCT116-CLK3+4siRNA,HCT116,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
1113,SA720T-2C,VBA0786,,,,[u'intartumoral heterogeneity']
737,SA533,CBX004,TNBreast tumor,,,[u'breast cancer xeno/genome evolution']
873,SA593N,MT3352_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
1494,SA939,VOA4488BC,,,,[u'intartumoral heterogeneity']
956,SA662N,Her2-20,Buffy coat,,,[u'her2 breast cancer']
181,SA091,TTR0001074,Breast Tumour,,,[u'triple negatives ']
182,SA091,TTR0001074,Breast Tumour,,,[u'triple negatives ']
1439,SA908,184hTERT-L9_99.5_p#8,184hTERT-L9_99.5,,,[u'breast cancer xeno/genome evolution']
122,SA058 renamed as SA052,IDC - TTR0001013,Breast Tumour,,,[u'triple negatives']
846,SA585,CT140,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1146,SA585,CT140,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1630,SA1005,#8 siPPP2R2A,T47 breast cancer cell line,,,[u'ppp2r2a']
1629,SA1004,#6 siPPP2R2A,T47 breast cancer cell line,,,[u'ppp2r2a']
1632,SA1007,siNT,T47 breast cancer cell line,,,[u'ppp2r2a']
1631,SA1006,3X (#5+#6+#8) siPPP2R2A,T47 breast cancer cell line,,,[u'ppp2r2a']
1794,SA1040N,"J16-2061T-BC (SM-170, #4)",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1625,SA1000,20170117ChIPnodrug,ChIP,,,[u'genomic instability and mutational signatures of cancer']
1628,SA1003,#5 siPPP2R2A,T47 breast cancer cell line,,,[u'ppp2r2a']
1627,SA1002,20161208ChIPCX5461,ChIP,,,[u'genomic instability and mutational signatures of cancer']
665,SA493N,VBA0303-CD3+, Pleural effusion ,,,[u'breast cancer xeno/genome evolution']
1107,SA720N,VBA0786,,,,[u'intartumoral heterogeneity']
1363,SA851-R1,231_CDK12_611si_2,MDA-MB-231,,,[u'takeda-japan-splicing project']
1633,SA1008,(-) control,T47 breast cancer cell line,,,[u'ppp2r2a']
1366,SA851-R2,231_CDK12_611si_3,MDA-MB-231,,,[u'takeda-japan-splicing project']
963,SA532-X0002-35333,X0002-35333,xenograft breast tumor,,,[u'breast cancer xeno/genome evolution']
962,SA532-X0002-35332,X0002-35332,xenograft breast tumor,,,[u'breast cancer xeno/genome evolution']
961,SA532-X0002-35331,X0002-35331,xenograft breast tumor,,,[u'breast cancer xeno/genome evolution']
1840,SA1052F,VOA7668F,,D4,D4,[u'ith immune']
452,SA233N,GT125,Buffy coat,,,[u'triple negatives']
1121,SA722N,VBA0794,,,,[u'intartumoral heterogeneity']
964,SA532-X0002-35334,X0002-35334,xenograft breast tumor,,,[u'breast cancer xeno/genome evolution']
380,SA353,HT29 Parental m7,Colorectal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
381,SA353,HT29 Parental m7,Colorectal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
639,SA451,HCT116-BRCA2-/-46-T3 100nM,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
803,SA577X14,STG139_X14_Cambridge,Xenograft Breast tumor-generation 14,,,[u'breast cancer xeno/genome evolution']
1536,SA822J,02946,,,,[u'intartumoral heterogeneity']
376,SA351,HT29 SutR m36,Colorectal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
377,SA351,HT29 SutR m36,Colorectal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
1534,SA822H,02946,,,,[u'intartumoral heterogeneity']
456,SA363,SKBR3 Lap R,mammary gland cell line,,,[u'miami lap r_cell lines']
458,SA363,SKBR3 Lap R,mammary gland cell line,,,[u'miami lap r_cell lines']
1311,SA822N,VOA4129BC,Blood,,,[u'intartumoral heterogeneity']
195,SA098,TB02.0281,TN- Breast Tumor,,,[u'triple negatives ']
196,SA098,TB02.0281,TN- Breast Tumor,,,[u'triple negatives ']
1538,SA822L,02946,,,,[u'intartumoral heterogeneity']
673,SA497N,VBA0607-SAL/10471,Saliva,,,[u'breast cancer xeno/genome evolution']
1739,SA1029N,1715 Leukos,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1395,SA868,B18 CX1 10^-8 2 D #3,HCT116,,,[u'genomic instability and mutational signatures of cancer']
1250,SA786,SKBR3_CDK12si_Dharmacon_2,SKBR3,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'takeda-japan-splicing project']
446,SA223N,GT048,Buffy coat,,,[u'triple negatives']
1531,SA822D,02946,,,,[u'intartumoral heterogeneity']
545,SA297N,GVM0131,Buffy coat,,,[u'triple negatives']
937,SA655N,MT486_BC,,v4 chemistry,v4 chemistry,[u'triple negatives']
944,SA658,Her2-6,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
173,SA087,TTR0001058,Breast Tumour,,,[u'rare breast cancer subtypes']
174,SA087,TTR0001058,Breast Tumour,,,[u'rare breast cancer subtypes']
171,SA086,TTR0001056,Breast Tumour,,,[u'rare breast cancer subtypes']
172,SA086,TTR0001056,Breast Tumour,,,[u'rare breast cancer subtypes']
1094,SA501X3A,VBA0662,,,,[u'breast cancer xeno/genome evolution']
163,SA082,IDC - TTR0001072,Breast Tumour,,,[u'triple negatives ']
164,SA082,IDC - TTR0001072,Breast Tumour,,,[u'triple negatives ']
1914,SA1072N,VBA0913,,F7,F7,[u'biopsy series']
1386,SA859-R2,231_T092_24h_1.5_3,MDA-MB-231,,,[u'takeda-japan-splicing project']
1288,SA814N,Her2-26,Blood,,,[u'her2 breast cancer']
1379,SA857-R1,231_T836_24h_1.5_2,MDA-MB-231,,,[u'takeda-japan-splicing project']
1485,SA930,,,,,[u'single cell project']
1377,SA858,231_T836_24h_0.5_1,MDA-MB-231,,,[u'takeda-japan-splicing project']
1886,SA1072T,VBA0913,,B4,B4,[u'biopsy series']
470,SA369,81674,Breast Tumour-from Cambridge,,,[u'metabric']
1361,SA852,231_scramSix2_1,MDA-MB-231,,,[u'takeda-japan-splicing project']
1362,SA853,231_CDK12_5149_1,MDA-MB-231,,,[u'takeda-japan-splicing project']
1359,SA850,siSRRM2 48hr,HCT116,,,[u'takeda-japan-splicing project']
1863,SA1060_2T,CBX036,,C1,C1,[u'biopsy series']
1375,SA856,231_T092_24h_0.5_1,MDA-MB-231,,,[u'takeda-japan-splicing project']
1376,SA857,231_T836_24h_1.5_1,MDA-MB-231,,,[u'takeda-japan-splicing project']
1369,SA854,231_KUTRsi_1,MDA-MB-231,,,[u'takeda-japan-splicing project']
1371,SA855,231_scramSi_1,MDA-MB-231,,,[u'takeda-japan-splicing project']
1079,SA608_3T,CBX026,,,,[u'breast cancer xeno/genome evolution']
126,SA062 renamed as SA056,IDC - TTR0001025,Breast Tumour,,,[u'triple negatives']
843,SA290N,MT1584 _BC,Buffy coat,,,[u'triple negatives']
1700,SA894X3_6R,"GCRC1784T P3-6R combined #1, 2, 3",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'metaplastic brca']
1894,SA1058T,CBX017,,B5,B5,[u'biopsy series']
1122,SA722T-1A,VBA0794,,,,[u'intartumoral heterogeneity']
1123,SA722T-1B,VBA0794,,,,[u'intartumoral heterogeneity']
1124,SA722T-1C,VBA0794,,,,[u'intartumoral heterogeneity']
1900,SA1058N,CBX017,,H5,H5,[u'biopsy series']
273,SA053N,TTR0001015,Buffy coat,,,[u'triple negatives']
1436,SA905,184hTERT-L9_WT_p#61,184hTERT-L9_WT,,,[u'breast cancer xeno/genome evolution']
1248,SA784,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
928,SA652,184hTert NIH CLK 1/4 Probe 5uM,,,,[u'takeda-japan-splicing project']
817,SA409,MT3120,TN- Breast Tumor,,,[u'triple negatives']
1903,SA1061N,CBX035,,C6,C6,[u'biopsy series']
1013,SA674N,MT3435_BC,Buffy coat,,,[u'triple negatives']
614,SA429,vba0569-PE,ER(+) - Bca - Pleural effusion ,"inadequate coverage after 3 lanes (19.42x). Library seems to have unusually high dup reads, 1 for every 2.5 reads. New library is being made (Mar, 16 2012), A21770: HY2538 is the sample ID since it's a hybrid of the two DNA submissions. ","inadequate coverage after 3 lanes (19.42x). Library seems to have unusually high dup reads, 1 for every 2.5 reads. New library is being made (Mar, 16 2012), A21770: HY2538 is the sample ID since it's a hybrid of the two DNA submissions. ",[u'breast cancer xeno/genome evolution']
1066,SA605N,CBX046,,,,[u'breast cancer xeno/genome evolution']
1426,SA899,V13-1784 buffy coat,,,,[u'metaplastic brca']
1002,SA394N,GT472_BC,Buffy coat,,,[u'triple negatives']
1857,SA1050N,VOA8553BC,,E6,E6,[u'ith immune']
965,SA532-X0002-3533C,X0002-3533C,xenograft breast tumor,,,[u'breast cancer xeno/genome evolution']
710,SA513,Takeda-8-GABAneuron#2,GABA neuron,,,[u'takeda-japan-splicing project']
1804,DAH228,VOA80B,,,,[u'fold back inversion']
1885,SA1062_3T,CBX045,,A4,A4,[u'biopsy series']
1434,SA903,SKBR3_KUTRsi_3,,,,[u'cdk13 (charge back to greg)']
1421,SA894,V2013-1784-1T,,,,[u'metaplastic brca']
1880,SA1061T,CBX035,,D3,D3,[u'biopsy series']
741,SA534N,CBX008,Buffy coat,,,[u'breast cancer xeno/genome evolution']
792,SA574X1,VBA0743,Xenograft Breast tumor-generation 1,tumor and normal sequenced by POG project -POG-31 sample,tumor and normal sequenced by POG project -POG-31 sample,[u'breast cancer xeno/genome evolution']
1422,SA895,GCRC1784T P1-7L,,,,[u'metaplastic brca']
1129,SA723T-1A,VBA0834,,,,[u'intartumoral heterogeneity']
304,SA093N,Camb 83021,Buffy coat,,,[u'triple negatives']
1131,SA723T-1C,VBA0834,,,,[u'intartumoral heterogeneity']
915,SA639,184hTert KH-CB19 0.2uM,,,,[u'takeda-japan-splicing project']
912,SA636,184hTert L41 1uM,,,,[u'takeda-japan-splicing project']
913,SA637,184hTert L41 5uM,,,,[u'takeda-japan-splicing project']
910,SA634,184hTert L41 0.2uM,,,,[u'takeda-japan-splicing project']
911,SA635,184hTert L41 0.5uM,,,,[u'takeda-japan-splicing project']
908,SA632,HCT116 NIH CLK 1/4 Probe 10uM,,,,[u'takeda-japan-splicing project']
909,SA633,184hTert L41 DMSO,,,,[u'takeda-japan-splicing project']
906,SA630,HCT116 NIH CLK 1/4 Probe 1uM,,,,[u'takeda-japan-splicing project']
907,SA631,HCT116 NIH CLK 1/4 Probe 5uM,,,,[u'takeda-japan-splicing project']
1006,SA667N,CT266_BC,Buffy coat,,,[u'triple negatives']
833,SA411N,MT2569_BC,Buffy coat,,,[u'triple negatives']
945,SA659,Her2-9,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
686,SA497X1,X0607-1,Xenograft breast tumor-generation 1,"pulled out due the xeno tumor faiure with STR genotyping assay; Therefore, indicating that the tumor could be non-human. ","pulled out due the xeno tumor faiure with STR genotyping assay; Therefore, indicating that the tumor could be non-human. ",[u'breast cancer xeno/genome evolution']
1016,SA677N,MT3588_BC,Buffy coat,,,[u'triple negatives']
757,SA542N,STG195_BC_Cambridge,Buffy coat,,,[u'breast cancer xeno/genome evolution']
1418,SA891,siSRSF6-2&3,HCT116-WT,,,[u'takeda-japan-splicing project']
1085,SA605X1,CBX046,,lack of SNP concordance with the matched tumor or normal,lack of SNP concordance with the matched tumor or normal,[u'breast cancer xeno/genome evolution']
1073,SA605T,CBX046,,,,[u'breast cancer xeno/genome evolution']
1065,SA604N,CBX038,,,,[u'breast cancer xeno/genome evolution']
862,SA402,VBA0435,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1161,SA402,VBA0435,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1032,SA685,DLD1_S1WT_P17,DLD,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1800,SA1043T,"J17-2089-T (B-322, #1)",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
864,SA404,VBA0467,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1162,SA404,VBA0467,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1049,SA702,HCT116_S1WT_P57,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1050,SA703,HCT116_S1B83_P64,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1047,SA700,HCT116_S1B46_P41,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1048,SA701,HCT116_S1B18_P41,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1856,SA1053N,VOA8342BC,,D6,D6,[u'ith immune']
1054,SA707,HCT116_S2B18_P20,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1051,SA704,HCT116_S1B46_P67,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1052,SA705,HCT116_S1B18_P68,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1333,SA828-R1,HCT116_DMSO,HCT116,,,[u'takeda-japan-splicing project']
1055,SA708,HCT116_S2B46_P20,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1056,SA709,HCT116_S2B83_P20,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1806,DAH172,VOA163A,,,,[u'fold back inversion']
1848,SA1053E,VOA7685E,,D5,D5,[u'ith immune']
82,SA034,VBA0038 pleural effusion metastasis ligated PCR amplicons,DNA fr. hu metastatic tumor,,,[u'lobular breast']
83,SA035,,CAPAN-1,,,[u'sirna screen']
123,SA059 renamed as SA053,IDC - TTR0001015,Breast Tumour,,,[u'triple negatives']
81,SA033,VBA0038 primary tumor ligated PCR,DNA fr.hu breast tumour tissue ,,,[u'lobular breast']
447,SA224N,MT0511  ,Buffy coat,,,[u'triple negatives']
1208,SA744,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1716,SA992N,J2015-1963 Buffy Coat,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
90,SA039,L9p12,184-hTERT L9 Clone,,,[u'h-tert']
91,SA039,L9p12,184-hTERT L9 Clone,,,[u'h-tert']
725,SA528,HCT116-GSK3-72h 1uM,HCT116,,,[u'takeda-japan-splicing project']
293,SA074N,IDC - TTR0001026,frozen normal,,,[u'triple negatives']
1034,SA687,DLD1_S1WT_P24,DLD,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
738,SA533N,CBX004,Buffy coat,,,[u'breast cancer xeno/genome evolution']
1869,SA1067_2T,CBX071,,A2,A2,[u'biopsy series']
1292,SA818N,Her2-2,Blood,"Not Sequence, not enough DNA","Not Sequence, not enough DNA",[u'her2 breast cancer']
719,SA522,HCT116-GSK3-24hCtrl,HCT116,,,[u'takeda-japan-splicing project']
720,SA523,HCT116-GSK3-24h0.5uM,HCT116,,,[u'takeda-japan-splicing project']
717,SA520,hTert-ctrlsiRNA,184-hTeRT,,,[u'takeda-japan-splicing project']
29,SA004-H3K27me3,,HCT116,,,['']
723,SA526,HCT116-GSK3-72hCtrl,HCT116,,,[u'takeda-japan-splicing project']
724,SA527,HCT116-GSK3-72h0.5uM,HCT116,,,[u'takeda-japan-splicing project']
721,SA524,HCT116-GSK3-24h 1uM,HCT116,,,[u'takeda-japan-splicing project']
722,SA525,HCT116-GSK3-24h 5uM,HCT116,,,[u'takeda-japan-splicing project']
751,SA539,HCT116-WT-ATCC-T3-6h1uM,HCT116,,,[u'takeda-japan-splicing project']
424,SA014-4,184-hTERT L2 passage 9,hTert cell line,,,[u'htert methylation']
428,SA014-4,184-hTERT L2 passage 9,hTert cell line,,,[u'htert methylation']
49,SA014-2,,,Validation of previous sequencing,Validation of previous sequencing,[u'h-tert']
867,SA587N,GT1150_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
750,SA538,HCT116-WT-ATCC-T3-6h500nM,HCT116,,,[u'takeda-japan-splicing project']
1095,SA718N,VBA0773,,,,[u'intartumoral heterogeneity']
1009,SA670N,MT2088_BC,Buffy coat,retrieved from GSC due to insuficient amounts,retrieved from GSC due to insuficient amounts,[u'triple negatives']
1818,SA1048,VOA6491,,F1,F1,[u'ith immune']
1021,SA683N,MT4584_BC,Buffy coat,,,[u'triple negatives']
314,SA104N,TB03.0391,Buffy coat,,,[u'triple negatives']
1802,SA1045,NSG,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1709,SA1044,T47D ,T47 breast cancer cell line,,,[u'single cell project']
877,SA597N,MT4444_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
1874,SA1059_3T,CBX030,,F2,F2,[u'biopsy series']
270,SA031N,VBA0132,Buffy coat,,,[u'triple negatives']
1075,SA606T,VBA0799,,,,[u'breast cancer xeno/genome evolution']
797,SA576N,CBX021,Normal,,,[u'breast cancer xeno/genome evolution']
112,SA050,,Total RNA from 184hTERT-L9 p10,Analysis to be done in Cambridge,Analysis to be done in Cambridge,[u'h-tert']
113,SA050,,Total RNA from 184hTERT-L9 p10,Analysis to be done in Cambridge,Analysis to be done in Cambridge,[u'h-tert']
644,SA456,DLD1-WT-ATCC-T1 100nM,DLD1,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
645,SA457,DLD1-WT-ATCC-T3 100nM,DLD1,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
642,SA454,HCT116-p53-/- T3 100nM,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
643,SA455,DLD1-WT-ATCC-DMSO,DLD1,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
640,SA452,HCT116-p53-/- DMSO,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
641,SA453,HCT116-p53-/- T1 100nM,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
638,SA450,HCT116-BRCA2-/-46-T1 100nM,HCT116,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
727,SA530,VBA0663,TN-Breast tumor,PCR free - plate based library prep -had to do 8 cycle of PCR,PCR free - plate based library prep -had to do 8 cycle of PCR,[u'breast cancer xeno/genome evolution']
1125,SA722T-2A,VBA0794,,,,[u'intartumoral heterogeneity']
374,SA350,HT29 SutR m39,Colorectal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
375,SA350,HT29 SutR m39,Colorectal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
1127,SA722T-2C,VBA0794,,,,[u'intartumoral heterogeneity']
1126,SA722T-2B,VBA0794,,,,[u'intartumoral heterogeneity']
1862,SA1061_2T,CBX043,,B1,B1,[u'biopsy series']
382,SA354,M24MET P m1,Melanoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
383,SA354,M24MET P m1,Melanoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
646,SA458,DLD1-WT-Horizon-DMSO,DLD1,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
647,SA459,DLD1-WT-Horizon-C,DLD1,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
1570,SA957,HCT WT CTL1 E2,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1569,SA956,HCT WT CTL1 B5,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1568,SA955,,"Primary Mammary Epithelial Cells Breast; Normal, Human PCS-600-010",,,[u'single cell project']
1509,SA954,TOV2978,,,,[u'intartumoral heterogeneity']
1508,SA953,TOV3291G,,,,[u'intartumoral heterogeneity']
1507,SA952,TOV1369,,,,[u'intartumoral heterogeneity']
1506,SA951,OV2978,,,,[u'intartumoral heterogeneity']
306,SA096N,VBA0290,Buffy coat,,,[u'triple negatives']
1423,SA896,GCRC1784T P1-8L,,,,[u'metaplastic brca']
1424,SA897,GCRC1784T P3-6R,,,,[u'metaplastic brca']
1906,SA1064N,CBX053,,F6,F6,[u'biopsy series']
66,SA024 (rename as SA018),IDC - TTR0001005,DNA fr.hu breast tumour tissue ,,,[u'triple negatives']
1770,SA1031N,"N2015-1944 01BC Aug28, 2015",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1420,SA893,siSRSF9-3,HCT116-WT,,,[u'takeda-japan-splicing project']
1572,SA959,HCT WT CTL1 D1,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1571,SA958,HCT WT CTL1 C4,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1883,SA1064T,CBX053,,G3,G3,[u'biopsy series']
705,SA508,Takeda-3-iPSC#3,iPSC,,,[u'takeda-japan-splicing project']
1769,SA1031T,"*N15-1944-4M  #1, #2",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1626,SA1001,20161208InputCX5461,ChIP,,,[u'genomic instability and mutational signatures of cancer']
1335,SA829-R1,HCT116_DMSO,HCT116,,,[u'takeda-japan-splicing project']
1109,SA720T-1B,VBA0786,,,,[u'intartumoral heterogeneity']
1110,SA720T-1C,VBA0786,,,,[u'intartumoral heterogeneity']
1108,SA720T-1A,VBA0786,,,,[u'intartumoral heterogeneity']
1810,DAH227A,VOA779A,,,,[u'fold back inversion']
275,SA056N,IDC - TTR0001025,frozen normal,,,[u'triple negatives']
611,SA418N,MT2621,Buffy coat,v3 chemistry for Illumina in place,v3 chemistry for Illumina in place,[u'triple negatives']
1896,SA1064_2T,CBX059,,D5,D5,[u'biopsy series']
1133,SA723T-2B,VBA0834,,,,[u'intartumoral heterogeneity']
338,SA214N,GVM0243,Buffy coat-from Alberta,,,[u'triple negatives']
1486,SA931,VOA1072 CL,,,,[u'intartumoral heterogeneity']
687,SA498X1,X0614-1,Xenograft breast tumor-generation 1,,,[u'breast cancer xeno/genome evolution']
1606,SA897oct,GCRC1784T-P3-6R - OCT,,,,[u'metaplastic brca']
378,SA352,HT29 Parental m4,Colorectal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
379,SA352,HT29 Parental m4,Colorectal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
395,SA206A, 9-08 , primary mammary epithelial cells-unsorted,,,[u'\xa0primary hmec']
530,SA238N,BM01-20,Buffy coat,,,[u'triple negatives']
588,SA238N,BM01-20,Buffy coat,,,[u'triple negatives']
1634,SA1009,#5 siPPP2R2A + E2,T47 breast cancer cell line,,,[u'ppp2r2a']
1368,SA853-R2,231_CDK12_5149_3,MDA-MB-231,,,[u'takeda-japan-splicing project']
1365,SA853-R1,231_CDK12_5149_2,MDA-MB-231,,,[u'takeda-japan-splicing project']
1790,SA1038N,V2016-2047 BC,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1331,SA827,OV2295-2,Ovary,,,[u'cell mixing']
1330,SA826,TOV2295,Ovary,,,[u'cell mixing']
1758,SA1022N,"V2015-1886 buffy coat feb24,2015",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1334,SA829,HCT116_DMSO,HCT116,,,[u'takeda-japan-splicing project']
1332,SA828,HCT116_DMSO,HCT116,,,[u'takeda-japan-splicing project']
1243,SA779,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1242,SA778,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
288,SA069N,IDC - TTR0001051,frozen normal,,,[u'triple negatives']
1237,SA773,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1236,SA772,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1235,SA771,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1234,SA770,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1241,SA777,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1240,SA776,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1239,SA775,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1238,SA774,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1488,SA933,VOA988BC,,,,[u'intartumoral heterogeneity']
1012,SA673N,MT3318_BC,Buffy coat,,,[u'triple negatives']
1767,SA1024N,V16-2055 BC,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1083,SA604_2X1,CBX038,,,,[u'breast cancer xeno/genome evolution']
1417,SA890,siSRSF6-1,HCT116-WT,,,[u'takeda-japan-splicing project']
729,SA530N,VBA0663,Blood,library constructed by Martin Hirst's lab for expedited sequencing - rapid 4x lanes seq,library constructed by Martin Hirst's lab for expedited sequencing - rapid 4x lanes seq,[u'breast cancer xeno/genome evolution']
197,SA099,TB02.0300,TN- Breast Tumor,,,[u'triple negatives ']
198,SA099,TB02.0300,TN- Breast Tumor,,,[u'triple negatives ']
37,SA009 -- renamed to SA002 used in HS0511,VBA0038,RNA fr. Human pleural effusion cells,,,['']
1425,SA898,GCRC1784T-P3-4L ,,,,[u'metaplastic brca']
69,SA027 (rename as SA030),IDC - TTR0001004,DNA fr.hu breast tumour tissue ,,,[u'triple negatives']
870,SA590N,MT1023_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
1433,SA902-R2,SKBR3_scramSix1,,,,[u'cdk13 (charge back to greg)']
1008,SA669N,MT1228_BC,Buffy coat,,,[u'triple negatives']
1432,SA902-R1,SKBR3_scramSix1,,,,[u'cdk13 (charge back to greg)']
957,SA663N,Her2-21,Buffy coat,,,[u'her2 breast cancer']
1878,SA1066_3T,CBX067,,B3,B3,[u'biopsy series']
1381,SA856-R1,231_T092_24h_0.5_2,MDA-MB-231,,,[u'takeda-japan-splicing project']
1385,SA856-R2,231_T092_24h_0.5_3,MDA-MB-231,,,[u'takeda-japan-splicing project']
1036,SA689,DLD1_S2WT_P14,DLD,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
157,SA078,IDC - TTR0001071,Breast Tumour,,,[u'triple negatives ']
158,SA078,IDC - TTR0001071,Breast Tumour,,,[u'triple negatives ']
1467,SA911X1,CBX044,,,,[u'xenograft']
445,SA220N,CT063,Buffy coat,,,[u'triple negatives']
390,SA360N,A1222 (Tail Snip),Cell lines from Park lab in Montreal,mouse tumors can't be used on human exome chips,mouse tumors can't be used on human exome chips,[u'resistant/met cell lines']
454,SA236N,MT0541,Buffy coat,,,[u'triple negatives']
52,SA015-2,,,Validation of previous sequencing,Validation of previous sequencing,[u'h-tert']
1128,SA723N,VBA0834,,,,[u'intartumoral heterogeneity']
1510,SA820A,01383,,,,[u'intartumoral heterogeneity']
1291,SA817N,Her2-11,Blood,,,[u'her2 breast cancer']
836,SA420N,MT2851_BC,Buffy coat,,,[u'triple negatives']
521,SA278,MT2209,TN- Breast Tumor,,,[u'triple negatives']
1419,SA892,siSRSF9-2,HCT116-WT,,,[u'takeda-japan-splicing project']
1483,SA928,GM18507,lyphoblastoid cell line,,,[u'single cell project']
522,SA277,MT2244,TN- Breast Tumor,,,[u'triple negatives']
507,SA273,MT0526,TN- Breast Tumor,,,[u'triple negatives']
512,SA271,MT0113,TN- Breast Tumor,,,[u'triple negatives']
1781,SA1035N,"V2016-2006 1BC Feb19, 2016",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1134,SA723T-2C,VBA0834,,,,[u'intartumoral heterogeneity']
1933,SA1085,,,,,['']
1860,SA1056,184-hTERT-22 clone ID 116.126,184 hTERT,,,['']
1957,SA1087,,,,,['']
1752,SA1016N,"V2015-1868 01BC Jan27, 2015",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1923,SA1081,,,,,[u'genomic instability and mutational signatures of cancer']
1922,SA1080,,,,,[u'genomic instability and mutational signatures of cancer']
1925,SA1083,,,,,['']
289,SA070N,IDC - TTR0001053,Buffy coat,,,[u'triple negatives']
1456,SA575X3,CBX016,,,,[u'xenograft']
985,SA670,MT2088,TN- Breast Tumor,retrieved from GSC due to insuficient amounts,retrieved from GSC due to insuficient amounts,[u'triple negatives']
1619,SA997N,"V2015-1905 01BC Mar26, 2015",GCRC1905 normal buffy coat,Tumour from McGill for Xenograft group,Tumour from McGill for Xenograft group,[u'metaplastic brca']
1605,SA897re,GCRC1784T-P3-6R - original,,,,[u'metaplastic brca']
971,SA535-X0011-2312C,X0011-2312C,xenograft breast tumor,,,[u'breast cancer xeno/genome evolution']
1867,SA1059T,CBX019,,G1,G1,[u'biopsy series']
1911,SA1069N,VBA0842,,C7,C7,[u'biopsy series']
1812,DG1198,VOA1798C,,,,[u'fold back inversion']
770,SA552,T47D siPPP2R2A CDT E2 6h -2,T47 breast cancer cell line,,,[u'pp2r2a project']
769,SA551,T47D siPPP2R2A CDT E2 6h -1,T47 breast cancer cell line,,,[u'pp2r2a project']
768,SA550,T47D siPPP2R2A CDT E2 6h -2,T47 breast cancer cell line,,,[u'pp2r2a project']
775,SA557,SKBR3-CDK12 siRNA (611)-4,SKBR3 ,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
36,SA008,,HCT116,,,[u'sirna screen']
773,SA555,SKBR3-scramble siRNA-4,SKBR3 ,,,[u'takeda-japan-splicing project']
772,SA554,SKBR3-scramble siRNA-2,SKBR3 ,,,[u'takeda-japan-splicing project']
33,SA005,,HCT116,,,[u'sirna screen']
820,SA413,MT3116,TN- Breast Tumor,,,[u'triple negatives']
777,SA559,SKBR3-untransfected-3,SKBR3 ,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
34,SA006,,HCT116,,,[u'sirna screen']
8,SA001,,,,,['']
1257,SA793,SA793,SW684,v4 chemistry,v4 chemistry,[u'takeda-japan-splicing project']
1755,SA1021N,"V15-1882-1N,2N,3N",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1624,SA999,20170117Inputnodrug,ChIP,,,[u'genomic instability and mutational signatures of cancer']
1618,SA998,GCRC 1840T P2-3L#2,Xenograft (GCRC1840),Tumour from McGill for Xenograft group,Tumour from McGill for Xenograft group,[u'metaplastic brca']
1902,SA1060N,CBX032,,B6,B6,[u'biopsy series']
1611,SA993,GCRC1924,Xenograft (x1735),Tumour from McGill for Xenograft group,Tumour from McGill for Xenograft group,[u'intartumoral heterogeneity']
835,SA413N,MT3116_BC,Buffy coat,,,[u'triple negatives']
1604,SA991,B18 PDS 36,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1603,SA990,B18 PDS 32,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1617,SA997,GCRC 1905-P1-6L PDX #2,Xenograft (GCRC1905),Tumour from McGill for Xenograft group,Tumour from McGill for Xenograft group,[u'metaplastic brca']
1613,SA995,GCRC1887,Xenograft (x1887),Tumour from McGill for Xenograft group,Tumour from McGill for Xenograft group,[u'intartumoral heterogeneity']
1612,SA994,GCRC1851,Xenograft (x1851),Tumour from McGill for Xenograft group,Tumour from McGill for Xenograft group,[u'intartumoral heterogeneity']
1254,SA790,SKBR3_KUTRsi_2,SKBR3,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'takeda-japan-splicing project']
368,SA347,786-0 SutR m22,Renal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
369,SA347,786-0 SutR m22,Renal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
893,SA617,HCT116 L41 10uM,,,,[u'takeda-japan-splicing project']
1614,SA1035,GCRC2006,Xenograft (x2006),Tumour from McGill for Xenograft group,Tumour from McGill for Xenograft group,[u'intartumoral heterogeneity']
372,SA349,786-0 Parental m28,Renal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
373,SA349,786-0 Parental m28,Renal carcinoma/xenografts,Xenografts from Pfizer,Xenografts from Pfizer,[u'resistant/met cell lines']
1260,SA796,HCT116 WT,HCT116 WT,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1888,SA1060T,CBX032,,D4,D4,[u'biopsy series']
887,SA611,,,,,[u'breast cancer xeno/genome evolution']
1620,SA998N,"V2014-1840 01BC Leukos Nov12, 2014",GCRC1840 normal buffy coat,Tumour from McGill for Xenograft group,Tumour from McGill for Xenograft group,[u'metaplastic brca']
888,SA612,HCT116 L41 DMSO,,,,[u'takeda-japan-splicing project']
679,SA500N,VBA0654-BC,Buffy coat,,,[u'breast cancer xeno/genome evolution']
621,SA433,184-hTeRT-L2-T3 100nM,184-hTeRT,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
1116,SA721T-1B,VBA0790,,,,[u'intartumoral heterogeneity']
1115,SA721T-1A,VBA0790,,,,[u'intartumoral heterogeneity']
889,SA613,HCT116 L41 0.2uM,,,,[u'takeda-japan-splicing project']
1719,SA1019N,J2015-1971 Buffy Coat,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
313,SA103N,TB03.0524,Buffy coat,,,[u'triple negatives']
879,SA599N,MT4475_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
882,SA402N,VBA0435,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
68,SA026 (rename as SA029),IDC - TTR0001002,DNA fr.hu breast tumour tissue ,,,[u'triple negatives']
800,SA541T,STG201_PE_Cambridge,Breast tumor,,,[u'breast cancer xeno/genome evolution']
1829,SA1051B,VOA7652B,,A3,A3,[u'ith immune']
1394,SA867,B18 CX5461 10^-8 2D #2,HCT116,,,[u'genomic instability and mutational signatures of cancer']
1393,SA866,B18 CX5461 10^-8 2D #1,HCT116,,,[u'genomic instability and mutational signatures of cancer']
1392,SA865,B18 Control #13,HCT116,,,[u'genomic instability and mutational signatures of cancer']
543,SA294N,GVM0029,Buffy coat,"removed due to inadequate amount of normal DNA availabe, determined after QC at GSC","removed due to inadequate amount of normal DNA availabe, determined after QC at GSC",[u'triple negatives']
1390,SA863,B18 Control #8,HCT116,,,[u'genomic instability and mutational signatures of cancer']
1389,SA862,B18 Control #4,HCT116,,,[u'genomic instability and mutational signatures of cancer']
1388,SA861,B18 Control #3,HCT116,,,[u'genomic instability and mutational signatures of cancer']
1387,SA860,B18 Control #1,HCT116,,,[u'genomic instability and mutational signatures of cancer']
1007,SA668N,GT618_BC,Buffy coat,,,[u'triple negatives']
1256,SA792,SKBR3_Ksi_Dharmacon_3,SKBR3,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'takeda-japan-splicing project']
1120,SA721T-2C,VBA0790,,,,[u'intartumoral heterogeneity']
1396,SA869,B18 CX5461 10^-8 2D #4,HCT116,,,[u'genomic instability and mutational signatures of cancer']
334,SA210N,MT0882,Buffy coat-from Alberta,,,[u'triple negatives']
1466,SA910X2,CBX023,,,,[u'xenograft']
970,SA535-X0011-23128,X0011-23128,xenograft breast tumor,,,[u'breast cancer xeno/genome evolution']
1778,SA1026N,"V2016-2001 1BC Feb03, 2016",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1003,SA395N,MT0596_BC,Buffy coat,,,[u'triple negatives']
1435,SA904,184hTERT-L9_WT_p#22,184hTERT-L9_WT,,,[u'breast cancer xeno/genome evolution']
1505,SA950,OV4485,,,,[u'intartumoral heterogeneity']
1437,SA906,184hTERT-L9_95.22_p#8,184hTERT-L9_95.22,,,[u'breast cancer xeno/genome evolution']
1438,SA907,184hTERT-L9_95.22_p#56,184hTERT-L9_95.22,,,[u'breast cancer xeno/genome evolution']
968,SA535-X0011-23126,X0011-23126,xenograft breast tumor,,,[u'breast cancer xeno/genome evolution']
969,SA535-X0011-23127,X0011-23127,xenograft breast tumor,,,[u'breast cancer xeno/genome evolution']
1431,SA902,SKBR3_scramSix1,,,,[u'cdk13 (charge back to greg)']
967,SA535-X0011-23125,X0011-23125,xenograft breast tumor,,,[u'breast cancer xeno/genome evolution']
1708,SA998X2_3L,GCRC1840T P2-3L #2,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'metaplastic brca']
795,SA575X1,CBX016,Xenograft Breast tumor-generation 1,,,[u'breast cancer xeno/genome evolution']
728,SA578N,VBA0633,Blood,NOTE: this sample was initially mistakently submitted as a normal for VBA0663 - the mix up was identified after the genome analysis. Therefore the sample IDs were chaned in the LIMS - PCR free - plate based library prep -had to do 8 cycle of PCR,NOTE: this sample was initially mistakently submitted as a normal for VBA0663 - the mix up was identified after the genome analysis. Therefore the sample IDs were chaned in the LIMS - PCR free - plate based library prep -had to do 8 cycle of PCR,[u'breast cancer xeno/genome evolution']
1901,SA1059N,CBX019,,A6,A6,[u'biopsy series']
67,SA025 (rename as SA028),IDC - TTR0001001,DNA fr.hu breast tumour tissue ,New RNA submitted due to first batch having low RIN,New RNA submitted due to first batch having low RIN,[u'triple negatives']
690,SA501X1,X0662-1,Xenograft breast tumor-generation 1,,,[u'breast cancer xeno/genome evolution']
448,SA225N,MT1034,Buffy coat,,,[u'triple negatives']
1384,SA857-R2,231_T836_24h_1.5_3,MDA-MB-231,,,[u'takeda-japan-splicing project']
193,SA097,TB02.0034,TN- Breast Tumor,,,[u'triple negatives ']
194,SA097,TB02.0034,TN- Breast Tumor,,,[u'triple negatives ']
296,SA077N,IDC - TTR0001070,Buffy coat,,,[u'triple negatives']
948,SA662,Her2-20,FFPE- Her2 breast Tumor,,,[u'her2 breast cancer']
1286,SA812N,Her2-15,Blood,,,[u'her2 breast cancer']
799,SA532-3T,CBX002,Breast tumor,,,[u'breast cancer xeno/genome evolution']
1084,SA604_3X3,CBX038,,,,[u'breast cancer xeno/genome evolution']
1540,SA823B,03159,,,,[u'intartumoral heterogeneity']
1255,SA791,SKBR3_Ksi_Dharmacon_2,SKBR3,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'takeda-japan-splicing project']
1018,SA679N,MT4149_BC,Buffy coat,,,[u'triple negatives']
561,SA067N,TTR0001055,Normal Tissue,,,[u'triple negatives']
1871,SA576_3T,CBX033,,C2,C2,[u'biopsy series']
1098,SA718T-1C,VBA0773,,,,[u'intartumoral heterogeneity']
874,SA594N,MT3402_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
1378,SA859,231_T092_24h_1.5_1,MDA-MB-231,,,[u'takeda-japan-splicing project']
1097,SA718T-1B,VBA0773,,,,[u'intartumoral heterogeneity']
866,SA586N,CT223_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
805,SA533-2T,CBX004,Breast tumor- second biopsy,,,[u'breast cancer xeno/genome evolution']
1096,SA718T-1A,VBA0773,,,,[u'intartumoral heterogeneity']
1926,SA1084,,,,,['']
541,SA273N,MT0526,Buffy coat,,,[u'triple negatives']
837,SA421N,MT3157_BC,Buffy coat,,,[u'triple negatives']
925,SA649,184hTert NIH CLK 1/4 Probe 0.2uM,,,,[u'takeda-japan-splicing project']
451,SA232N,MT0365,Buffy coat,,,[u'triple negatives']
587,SA232N,MT0365,Buffy coat,,,[u'triple negatives']
886,SA603,,,,,[u'breast cancer xeno/genome evolution']
885,SA602,,,samples with xenos that were sent to Pfizer but not sent to GSC for sequencing,samples with xenos that were sent to Pfizer but not sent to GSC for sequencing,[u'breast cancer xeno/genome evolution']
861,SA601,UT475,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1160,SA601,UT475,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
860,SA600,MT4538,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
1159,SA600,MT4538,TN- Breast Tumor,v4 chemistry,v4 chemistry,[u'triple negatives']
332,SA208N,CT110,Buffy coat-from Alberta,,,[u'triple negatives']
936,SA654N,MT3442_BC,,v4 chemistry,v4 chemistry,[u'triple negatives']
655,SA467,HCT116-WT-ATCC-T3-6h500nM,HCT116,,,[u'takeda-japan-clki']
1775,SA1032N,V2015-1979 BC,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1337,SA830-R1,HCT116_T3-0.5,HCT116,,,[u'takeda-japan-splicing project']
1746,SA1028N,"V2014-1834 01BC Levkos Oct22, 2014",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
671,SA496N,VBA0532-CD3+, Pleural effusion ,,,[u'breast cancer xeno/genome evolution']
1542,SA823D,03159,,,,[u'intartumoral heterogeneity']
1545,SA823G,03159,,,,[u'intartumoral heterogeneity']
1544,SA823F,03159,,,,[u'intartumoral heterogeneity']
1360,SA851,231_CDK12_611si_1,MDA-MB-231,,,[u'takeda-japan-splicing project']
919,SA643,184hTert KH-CB19 10uM,,,,[u'takeda-japan-splicing project']
1915,SA1073N,VBA1214,,G7,G7,[u'biopsy series']
918,SA642,184hTert KH-CB19 5uM,,,,[u'takeda-japan-splicing project']
1890,SA1073T,VBA1214,,F4,F4,[u'biopsy series']
654,SA466,HCT116-WT-ATCC-T3-6h100nM,HCT116,,,[u'takeda-japan-clki']
276,SA063N,IDC - TTR0001042,Buffy coat,,,[u'triple negatives']
1868,SA1060_3T,CBX042,,H1,H1,[u'biopsy series']
1834,SA1051G,VOA7652G,,F3,F3,[u'ith immune']
1203,SA739,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1202,SA738,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1201,SA737,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1200,SA736,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1199,SA735,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1198,SA734,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1197,SA733,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1145,SA732,HCT116-B18-cx5461 10^-7,HCT116-B18_p53-/-_Caldas lab-p29, with FASTQ ($75/10files), with FASTQ ($75/10files),[u'genomic instability and mutational signatures of cancer']
1144,SA731,HCT116-B18-cx5461 10^-8,HCT116-B18_p53-/-_Caldas lab-p29, with FASTQ ($75/10files), with FASTQ ($75/10files),[u'genomic instability and mutational signatures of cancer']
1143,SA730,HCT116-B18-cx5461 10^-9,HCT116-B18_p53-/-_Caldas lab-p29, with FASTQ ($75/10files), with FASTQ ($75/10files),[u'genomic instability and mutational signatures of cancer']
714,SA517,Takeda-12-DAneuron#3,DA neuron,,,[u'takeda-japan-splicing project']
713,SA516,Takeda-11-DA neuron#2,DA neuron,SA516 and SA517 RNA samples were pooled before library construction due to insufficiency of the amount of individual samples,SA516 and SA517 RNA samples were pooled before library construction due to insufficiency of the amount of individual samples,[u'takeda-japan-splicing project']
104,SA043,,HCT116,,,['']
711,SA514,Takeda-9-GABAneuron#3,GABA neuron,,,[u'takeda-japan-splicing project']
106,SA045,,HCT116,,,['']
105,SA044,,HCT116,,,['']
108,SA047,,Total RNA from H-106-04-A Luminal,Analysis to be done in Cambridge,Analysis to be done in Cambridge,['']
107,SA046,,HCT116,,,['']
110,SA049,,Total RNA from 184hTERT-L2 p10,Analysis to be done in Cambridge,Analysis to be done in Cambridge,[u'h-tert']
111,SA049,,Total RNA from 184hTERT-L2 p10,Analysis to be done in Cambridge,Analysis to be done in Cambridge,[u'h-tert']
109,SA048,,Total RNA from H-106-04-B Basal,Analysis to be done in Cambridge,Analysis to be done in Cambridge,['']
716,SA519,SKBR3-CDK12iRNA,SKBR3,,,[u'takeda-japan-splicing project']
715,SA518,SKBR3-ctrlsiRNA,SKBR3,,,[u'takeda-japan-splicing project']
506,SA284,MT0446,TN- Breast Tumor,,,[u'triple negatives']
1045,SA698,HCT116_S1WT_P36,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
523,SA282,MT2674 (2374),TN- Breast Tumor,,,[u'triple negatives']
398,SA217N,GT278,Buffy coat-from Alberta,,,[u'triple negatives']
1474,SA919X1,VBA0847,,,,[u'xenograft']
1041,SA694,HCT116_S1B83_P17,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
831,SA407N,MT3305_BC,Buffy coat,,,[u'triple negatives']
1043,SA696,HCT116_S1B46_P18,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1428,SA901,231_CDK13_5449si_1,,,,[u'cdk13 (charge back to greg)']
1037,SA690,DLD1_S2Bn_P20,DLD,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1038,SA691,DLD1_S2Bn_P28,DLD,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1039,SA692,DLD1_S2WT_P29,DLD,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1040,SA693,HCT116_S1WT_P2,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1861,SA722_2T,CBX061,,A1,A1,[u'biopsy series']
1917,SA1075,SSM2 22D1,Malignant synovial sarcoma,,,[u'single cell project']
1918,SA1076,,,,,[u'genomic instability and mutational signatures of cancer']
1919,SA1077,,,,,[u'genomic instability and mutational signatures of cancer']
822,SA421,MT3157,TN- Breast Tumor,,,[u'triple negatives']
1821,SA1049C,VOA7640C,,A2,A2,[u'ith immune']
1820,SA1049B,VOA7640B,,H1,H1,[u'ith immune']
658,SA470,HCT116-WT-ATCC-T3-6h10uM,HCT116,,,[u'takeda-japan-clki']
1853,SA1049N,VOA8124BC,,A6,A6,[u'ith immune']
1920,SA1078,,,,,[u'genomic instability and mutational signatures of cancer']
1921,SA1079,,,,,[u'genomic instability and mutational signatures of cancer']
1367,SA852-R2,231_scramSix2_3,MDA-MB-231,,,[u'takeda-japan-splicing project']
1855,SA1052N,VOA8262BC,,C6,C6,[u'ith immune']
1596,SA983,B18 CX5461 10^-8 2d 21,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
804,SA577MX0,STG139_MX0_Cambridge,Xenograft metastatic Breast tumor-generation 1,,,[u'breast cancer xeno/genome evolution']
682,SA493X1,X0303-2,Xenograft breast tumor-generation 1,,,[u'breast cancer xeno/genome evolution']
1831,SA1051D,VOA7652D,,C3,C3,[u'ith immune']
1734,SA1025N,"V2015-1863 01BC Jan16, 2015",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1017,SA678N,MT3840_BC,Buffy coat,,,[u'triple negatives']
781,SA563,184htert-CDK12 siRNA (611)-3,184-hTert,RNA-spike-in,RNA-spike-in,[u'takeda-japan-splicing project']
1892,SA1074T,VBA1367,,H4,H4,[u'biopsy series']
1682,SA1034X1_1R,GCRC1986L-P1-1R PDX #2,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'metaplastic brca']
1427,SA900,NOG female tail DNA,,,,[u'metaplastic brca']
1019,SA680N,MT4195_BC,Buffy coat,,,[u'triple negatives']
1071,SA604_2T,CBX038,,,,[u'breast cancer xeno/genome evolution']
651,SA463,DLD1-BRCA2-/-T3 100nM,DLD1,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
650,SA462,DLD1-BRCA2-/- T1 100nM,DLD1,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
649,SA461,DLD1-BRCA2-/- DMSO,DLD1,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
648,SA460,DLD1-WT-Horizon-T3 100nM,DLD1,v3 chemistry-indexed libraries-2/lane,v3 chemistry-indexed libraries-2/lane,[u'takeda-japan-clki']
954,SA660N,Her2-12,Buffy coat,,,[u'her2 breast cancer']
1803,DAH204,VOA40D,,,,[u'fold back inversion']
653,SA465,HCT116-WT-ATCC-T3-6h50nM,HCT116,,,[u'takeda-japan-clki']
652,SA464,HCT116-WT-ATCC-T3-6hctrl,HCT116,,,[u'takeda-japan-clki']
360,SA343,NCIH1975_804R_CLONE 6,NSCLC*,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
361,SA343,NCIH1975_804R_CLONE 6,NSCLC*,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
657,SA469,HCT116-WT-ATCC-T3-6h5uM,HCT116,,,[u'takeda-japan-clki']
656,SA468,HCT116-WT-ATCC-T3-6h1uM,HCT116,,,[u'takeda-japan-clki']
266,SA017N,TTR0001003,Buffy coat,,,[u'triple negatives']
1841,SA1052G,VOA7668G,,E4,E4,[u'ith immune']
1442,SA493X4,VBA0303,,,,[u'xenograft']
364,SA345,NCIH1975_804R_CLONE 14,NSCLC*,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
365,SA345,NCIH1975_804R_CLONE 14,NSCLC*,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
1495,SA940,VOA5218 CL,,,,[u'intartumoral heterogeneity']
1496,SA941,VOA3994a,,,,[u'intartumoral heterogeneity']
1497,SA942,VOA4161BC,,,,[u'intartumoral heterogeneity']
1498,SA943,VOA3027a,,,,[u'intartumoral heterogeneity']
1499,SA944,VOA2905BC,,,,[u'intartumoral heterogeneity']
1500,SA945,VOA2411a,,,,[u'intartumoral heterogeneity']
1501,SA946,VOA2641BC,,,,[u'intartumoral heterogeneity']
1502,SA947,VOA6034a,,,,[u'intartumoral heterogeneity']
1503,SA948,OV866(2),,,,[u'intartumoral heterogeneity']
1504,SA949,OV1369 (2),,,,[u'intartumoral heterogeneity']
30,SA004-H3K4me3,,HCT116,,,['']
1837,SA1052C,VOA7668C,,A4,A4,[u'ith immune']
1593,SA980,B18 CX5461 10^-8 2d 12,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1836,SA1052B,VOA7668B,,H3,H3,[u'ith immune']
1798,SA1042N,V2016-2080 BC,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1594,SA981,B18 CX5461 10^-8 2d 16,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
362,SA344,NCIH1975_804R_CLONE 8,NSCLC*,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
363,SA344,NCIH1975_804R_CLONE 8,NSCLC*,Cell lines from Pfizer,Cell lines from Pfizer,[u'resistant/met cell lines']
610,SA417N,MT3062,Buffy coat,v3 chemistry for Illumina in place,v3 chemistry for Illumina in place,[u'triple negatives']
92,SA040,L2p12,184-hTERT L2 Clone,,,[u'h-tert']
93,SA040,L2p12,184-hTERT L2 Clone,,,[u'h-tert']
61,SA019,,HCT116,,,[u'sirna screen']
712,SA515,Takeda-10-DA neuron#1,DA neuron,,,[u'takeda-japan-splicing project']
453,SA235N,MT0382,Buffy coat,,,[u'triple negatives']
1548,SA824A,03380,,,,[u'intartumoral heterogeneity']
1550,SA824C,03380,,,,[u'intartumoral heterogeneity']
894,SA618,HCT116 KH-CB19 0.2uM,,,,[u'takeda-japan-splicing project']
1553,SA824F,03380,,,,[u'intartumoral heterogeneity']
1290,SA816N,Her2-13,Blood,,,[u'her2 breast cancer']
1555,SA824H,03380,,,,[u'intartumoral heterogeneity']
1556,SA824I,03380,,,,[u'intartumoral heterogeneity']
1787,SA1037N,"J16-2029-N (T-684, #5)",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1323,SA824N,VOA4821BC,Blood,,,[u'intartumoral heterogeneity']
709,SA512,Takeda-7-GABAneuron#1,GABA neuron,,,[u'takeda-japan-splicing project']
1811,DG1135,VOA1749B,,,,[u'fold back inversion']
708,SA511,Takeda-6-NPC#3,NPC,,,[u'takeda-japan-splicing project']
1601,SA988,B18 PDS 2d 27,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
707,SA510,Takeda-5-NPC#2,NPC,,,[u'takeda-japan-splicing project']
1710,SA1017N,J2015-1876 Buffy Coat,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1195,SA501X1A,,,v4 chemistry,v4 chemistry,[u'breast cancer xeno/genome evolution']
1602,SA989,B18 PDS 29,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1490,SA935,VOA1621a,,,,[u'intartumoral heterogeneity']
1489,SA934,VOA2008 CL,,,,[u'intartumoral heterogeneity']
1492,SA937,VOA2900 CL,,,,[u'intartumoral heterogeneity']
895,SA619,HCT116 KH-CB19 0.5uM,,,,[u'takeda-japan-splicing project']
1347,SA838,HCT116_KHCB19-10.0_Oxf,HCT116,,,[u'takeda-japan-splicing project']
1348,SA839,HCT116_KHCB19-1.0_Tak,HCT116,,,[u'takeda-japan-splicing project']
1725,SA994N,"V2014-1851 BC Levkos Dec9, 2014",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1487,SA932,VOA1425CL,,,,[u'intartumoral heterogeneity']
1343,SA834,HCT116_KHCB19-5.0_Oxf,HCT116,,,[u'takeda-japan-splicing project']
1344,SA835,HCT116_KHCB19-10.0_Oxf,HCT116,,,[u'takeda-japan-splicing project']
1345,SA836,HCT116_KHCB19-1.0_Oxf,HCT116,,,[u'takeda-japan-splicing project']
1346,SA837,HCT116_KHCB19-5.0_Oxf,HCT116,,,[u'takeda-japan-splicing project']
1336,SA830,HCT116_T3-0.5,HCT116,,,[u'takeda-japan-splicing project']
1338,SA831,HCT116_T3-1.0,HCT116,,,[u'takeda-japan-splicing project']
1340,SA832,HCT116_T3-5.0,HCT116,,,[u'takeda-japan-splicing project']
1342,SA833,HCT116_KHCB19-1.0_Oxf,HCT116,,,[u'takeda-japan-splicing project']
771,SA553N,,NRG mouse,sequenced at GeneWiz,sequenced at GeneWiz,[u'breast cancer xeno/genome evolution']
64,SA022,,HCT116,,,[u'sirna screen']
1854,SA1051N,VOA8184BC,,B6,B6,[u'ith immune']
818,SA411,MT2569,TN- Breast Tumor,,,[u'triple negatives']
269,SA030N,TTR0001004,Buffy coat,,,[u'triple negatives']
400,SA030N,TTR0001004,Buffy coat,,,[u'triple negatives']
881,SA601N,UT475_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
1469,SA913X1,CBX052,,,,[u'xenograft']
1728,SA920N,"1735 Levkos July23, 2013",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'genome-hiseqx']
1607,SA897snap,GCRC1784T-P3-6R - SNAP,,,,[u'metaplastic brca']
556,SA277N,MT2244,Buffy coat,,,[u'triple negatives']
613,SA425N,MT2932,Buffy coat,v3 chemistry for Illumina in place,v3 chemistry for Illumina in place,[u'triple negatives']
1078,SA608_2T,CBX022,,,,[u'breast cancer xeno/genome evolution']
1895,SA1057_4T,CBX057,,C5,C5,[u'biopsy series']
420,SA228N,MT0398,Buffy coat,T/N pair genotyped at CTAG,T/N pair genotyped at CTAG,[u'triple negatives']
1213,SA749,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1909,SA1067N,CBX068,,A7,A7,[u'biopsy series']
1616,SA532X8B,SA532X8B-X0002-35337322-Treated,Xenograft,,,[u'intartumoral heterogeneity']
1112,SA720T-2B,VBA0786,,,,[u'intartumoral heterogeneity']
1111,SA720T-2A,VBA0786,,,,[u'intartumoral heterogeneity']
1615,SA532X8A,SA532X8A- X0002-35337321-Untreat,Xenograft,,,[u'intartumoral heterogeneity']
1881,SA1067T,CBX068,,E3,E3,[u'biopsy series']
1101,SA719N,VBA0774,,,,[u'intartumoral heterogeneity']
62,SA020,,HCT116,,,[u'sirna screen']
312,SA102N,BB98.0097,Buffy coat,,,[u'triple negatives']
1074,SA605_2T,CBX046,,,,[u'breast cancer xeno/genome evolution']
1081,SA610T,CBX029,,,,[u'breast cancer xeno/genome evolution']
303,SA092N,Camb 83004,Buffy coat,previously on HOLD-released for EXCAP (50 Mb) on Dec 18th,previously on HOLD-released for EXCAP (50 Mb) on Dec 18th,[u'triple negatives']
524,SA028N,TTR0001001,Buffy coat,,,[u'triple negatives']
1701, SA894X3_4L ,"GCRC1784T-P3-4L combined #1, 2, 3 10/02/2016",,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'metaplastic brca']
26,SA003-H3K4me3,,HCT116,,,['']
1263,SA799,HCT116 WT,HCT116 WT,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1262,SA798,HCT116 WT,HCT116 WT,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
25,SA003-H3K27me3,,HCT116,,,['']
883,SA403N,VBA0195,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
1042,SA695,HCT116_S1B18_P18,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1444,SA495X5,VBA0509,,,,[u'xenograft']
684,SA495X4,X0509-XXX1,Xenograft breast tumor-generation 4,High reagent read (15%) and 17% mouse read,High reagent read (15%) and 17% mouse read,[u'breast cancer xeno/genome evolution']
271,SA051N,TTR0001012,Buffy coat,,,[u'triple negatives']
975,SA665N,MT4386_BC,Buffy coat,,,[u'triple negatives']
1259,SA795,SA795,HT-1080,v4 chemistry,v4 chemistry,[u'takeda-japan-splicing project']
1258,SA794,SA794,SW872,v4 chemistry,v4 chemistry,[u'takeda-japan-splicing project']
1261,SA797,HCT116 WT,HCT116 WT,ERCC RNA-spike-in,ERCC RNA-spike-in,[u'genomic instability and mutational signatures of cancer']
1692,SA894T,V2013-1784-1T,,Dr. Morag pays half on seq.,Dr. Morag pays half on seq.,[u'metaplastic brca']
337,SA213N,MT0620,Buffy coat-from Alberta,,,[u'triple negatives']
1044,SA697,HCT116_S1WT_P18,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1891,SA1069T,VBA0842,,G4,G4,[u'biopsy series']
1468,SA912X3,CBX051,,,,[u'xenograft']
1046,SA699,HCT116_S1B83_P37,HCT116,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1830,SA1051C,VOA7652C,,B3,B3,[u'ith immune']
1228,SA764,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1229,SA765,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1230,SA766,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1231,SA767,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1224,SA760,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1225,SA761,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1226,SA762,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1227,SA763,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
923,SA647,184hTert Z110128700 5uM,,,,[u'takeda-japan-splicing project']
922,SA646,184hTert Z110128700 1uM,,,,[u'takeda-japan-splicing project']
921,SA645,184hTert Z110128700 0.5uM,,,,[u'takeda-japan-splicing project']
920,SA644,184hTert Z110128700 0.2uM,,,,[u'takeda-japan-splicing project']
1232,SA768,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1233,SA769,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
917,SA641,184hTert KH-CB19 1uM,,,,[u'takeda-japan-splicing project']
916,SA640,184hTert KH-CB19 0.5uM,,,,[u'takeda-japan-splicing project']
825,SA427,CT176,TN- Breast Tumor,,,[u'triple negatives']
824,SA426,MT3042,TN- Breast Tumor,,,[u'triple negatives']
1513,SA820D,01383,,,,[u'intartumoral heterogeneity']
823,SA424,MT3315,TN- Breast Tumor,,,[u'triple negatives']
489,SA388,Takeda-7-12Adrenal,Adrenal,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
924,SA648,184hTert Z110128700 10uM,,,,[u'takeda-japan-splicing project']
487,SA386,Takeda-1-5Pituitary,Pituitary,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
488,SA387,Takeda-7-12Pituitary,Pituitary,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
485,SA384,Takeda-1-5Thyroid,Thyroid,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
486,SA385,Takeda-7-12Thyroid,Thyroid,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
483,SA382,Takeda-R2Visceral Aipose,Visceral Adipose (WAT),Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
484,SA383,Takeda-R10Visceral Aipose,Visceral Adipose (WAT),Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
481,SA380,Takeda-4Jejunum,Jejunum,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
482,SA381,Takeda-7Jejunum,Jejunum,Takeda Cambridge,Takeda Cambridge,[u'takeda-diet transcription regulation']
1597,SA984,B18 CX5461 10^-8 2d 23,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1598,SA985,B18 CX5461 10^-8 2d 24,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1599,SA986,B18 PDS 5,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1600,SA987,B18 PDS 2d 21,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
766,SA548,T47D siPPP2R2A CDT -2,T47 breast cancer cell line,,,[u'pp2r2a project']
767,SA549,T47D siPPP2R2A CDT E2 6h -1,T47 breast cancer cell line,withdrawn part way through library construction,withdrawn part way through library construction,[u'pp2r2a project']
1595,SA982,B18 CX5461 10^-8 2d 20,Cell Line,,,[u'genomic instability and mutational signatures of cancer']
1011,SA672N,MT3142_BC,Buffy coat,,,[u'triple negatives']
762,SA544,T47D siNT CDT -2,T47 breast cancer cell line,,,[u'pp2r2a project']
763,SA545,T47D siNT CDT E2 6h-1,T47 breast cancer cell line,,,[u'pp2r2a project']
764,SA546,T47D siNT CDT E2 6h-2,T47 breast cancer cell line,,,[u'pp2r2a project']
765,SA547,T47D siPPP2R2A CDT -1,T47 breast cancer cell line,,,[u'pp2r2a project']
752,SA540,HCT116-WT-ATCC-T3-6h5uM,HCT116,,,[u'takeda-japan-splicing project']
753,SA541,STG201_PE_Cambridge,Breast tumor,PCR free - plate based library prep,PCR free - plate based library prep,[u'breast cancer xeno/genome evolution']
756,SA542,STG195_PE_Cambridge,Breast tumor,PCR free - plate based library prep -had to do 8 cycle pCR,PCR free - plate based library prep -had to do 8 cycle pCR,[u'breast cancer xeno/genome evolution']
761,SA543,T47D siNT CDT -1,T47 breast cancer cell line,,,[u'pp2r2a project']
865,SA585N,CT140_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
422,SA230N,MT0675,Buffy coat,T/N pair genotyped at CTAG,T/N pair genotyped at CTAG,[u'triple negatives']
1100,SA718T-2B,VBA0773,,,,[u'intartumoral heterogeneity']
1209,SA745,,,v4 chemistry,v4 chemistry,[u'genomic instability and mutational signatures of cancer']
1889,SA1071T,VBA0910,,E4,E4,[u'biopsy series']
826,SA428,MT3038,TN- Breast Tumor,,,[u'triple negatives']
1472,SA916X1,CBX077,,,,[u'xenograft']
664,SA493,VBA0303-CD45-,ER(+) - Bca - Pleural effusion ,,,[u'breast cancer xeno/genome evolution']
670,SA496,VBA0532-CD45-,ER(+) - Bca - Pleural effusion ,,,[u'breast cancer xeno/genome evolution']
672,SA497,VBA0607,Breast tumor,"pulled out due the xeno tumor faiure with STR genotyping assay; Therefore, indicating that the tumor could be non-human. ","pulled out due the xeno tumor faiure with STR genotyping assay; Therefore, indicating that the tumor could be non-human. ",[u'breast cancer xeno/genome evolution']
666,SA494,VBA0459-CD45-,ER(+) - Bca - Pleural effusion ,,,[u'breast cancer xeno/genome evolution']
668,SA495,VBA0509-CD45-,TNBCa - Pleural effusion,,,[u'breast cancer xeno/genome evolution']
557,SA282N,MT2373 ,Buffy coat,,,[u'triple negatives']
871,SA591N,MT1525_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
674,SA498,VBA0614,Breast tumor,,,[u'breast cancer xeno/genome evolution']
676,SA499,VBA0616,TN- Breast Tumor,,,[u'breast cancer xeno/genome evolution']
1103,SA719T-1B,VBA0774,,,,[u'intartumoral heterogeneity']
1104,SA719T-1C,VBA0774,,,,[u'intartumoral heterogeneity']
880,SA600N,MT4538_BC,Buffy coat,v4 chemistry,v4 chemistry,[u'triple negatives']
1102,SA719T-1A,VBA0774,,,,[u'intartumoral heterogeneity']
